Antibodies capable of binding to the coagulation factor XIa and uses thereof

ABSTRACT

The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. patentapplication Ser. No. 15/691,731, filed Aug. 30, 2017, which is adivisional application of U.S. patent application Ser. No. 14/400,281,which adopts the international filing date of May 8, 2013, now U.S. Pat.No. 9,783,614, which is the U.S. national stage of Int'l Application No.PCT/EP2013/059618, filed May 8, 2013, which claims priority benefit ofprovisional Application No. 61/817,675, filed Apr. 30, 2013, ApplicationNo. EP 13150361.7, filed Jan. 7, 2013, and Application No. EP12181697.9, filed Aug. 24, 2012, and Application No. EP 12167438.6,filed May 10, 2012.

SUBMISSION OF SEQUENCE LISTING AS ASCII TEXT FILE

The content of the following submission on ASCII text file isincorporated herein by reference in its entirety: a computer readableform (CRF) of the Sequence Listing (file name:777052030901SequenceListing.TXT, date recorded: Mar. 4, 2019, size: 127KB).

FIELD OF THE INVENTION

The present invention relates to antibodies capable of binding to thecoagulation Factor XI and/or its activated form factor XIa and methodsof use thereof, particularly methods of use as agents inhibitingplatelet aggregation and by this inhibits thrombus formation.

BACKGROUND OF THE INVENTION

In 1964 Macfarlane and Davie & Ratnoff [Macfarlane R G. An enzymecascade in the blood clotting mechanism, and its function as abiochemical amplifier. Nature 1964; 202: 498-9.; Davie E W, Ratnoff O D.Waterfall sequence for intrinsic blood clotting. Science 1964; 145:1310-2.] introduced their cascade hypotheses for the process of bloodcoagulation. Since then, our knowledge of the function of coagulation invivo has grown. In the last years, the theory of two distinct routes,the so called the extrinsic and intrinsic pathway, that initiatecoagulation and converge in a common pathway, ultimately leading tothrombin generation and fibrin deposition, has been revised. In thecurrent model initiation of coagulation occurs when the plasma proteaseactivated factor VII comes into contact and by this forms a complex,with Tissue Factor (TF). This Tissue Factor-FVIIa complex can activatethe zymogen FX into its active form FXa, which on his part can convertprothrombin (coagulation factor II) into thrombin (IIa). Thrombin, a keyplayer in coagulation, in turn can catalyze the conversion of fibrinogeninto fibrin. Additionally, thrombin activates specific receptorsexpressed by platelets, which leads to the activation of the latter.Activated platelets in combination with fibrin are essential for clotformation and therefore are fundamental players of normal hemostasis.

The second amplification route is formed by the coagulation factor XI(FXI). It is well confirmed that FXI is, like the other members of thecoagulation cascade, a plasma serine protease zymogen with a key role inbridging the initiation phase and the amplification phase of bloodcoagulation in vivo [Davie E W, Fujikawa K, Kisiel W. The coagulationcascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-70; Gailani D, Broze Jr G J. Factor XI activation in a revisedmodel of blood coagulation. Science 1991; 253:909-12; Kravtsov D V,Matafonov A, Tucker E I, Sun M F, Walsh P N, Gruber A, et al. Factor XIcontributes to thrombin generation in the absence of factor XII. Blood2009; 114: 452-8.3-5]. FXI deficiency usually does not lead tospontaneous bleeding, but is associated with increased risk of bleedingwith hemostatic challenges, while the severity of bleeding correlatespoorly with the plasma level of FXI. Severe FXI deficiency in humans hascertain protective effects from thrombotic diseases [Salomon O,Steinberg D M, Zucker M, Varon D, Zivelin A, Seligshon U. Patients withsevere factor XI deficiency have a reduced incidence of deep-veinthrombosis. Thromb Haemost 2011; 105:269-73; Salomon O, Steinberg D M,Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemicstroke in patients with severe factor XI deficiency. Blood 2008;111:4113-7]. Yet, a high level of FXI has been associated withthrombotic events [Meijers J C, Tekelenburg W L, Bouma B N, Bertina R M,Rosendaal F R. High levels of coagulation factor XI as a risk factor forvenous thrombosis. N Engl J Med 2000; 342:696-701]. Inhibition of FXIhas therefore been proposed as a novel approach in the development ofnew antithrombotics to achieve an improved benefit-risk ratio. Thus,there is still a high medical need for anti-thrombotic, anti-plateletdrugs that blocks intravascular thrombosis efficaciously withoutdebilitating hemostasis.

BRIEF SUMMARY OF THE INVENTION

In recent years, the development of novel antithrombotic agents has madegreat progress; nevertheless, undesired bleeding events caused by theseagents are still a serious problem. Therefore, the optimalantithrombotic compound which would ideally inhibit thrombosis but sparehemostasis is yet to be discovered.

Coagulation factor XI (FXI/FXIa) interacts with platelet receptorapoER2. The present invention demonstrates for the first time thatinhibiting FXI/FXIa activity interferes with the process of pathologicalplatelet activation and platelet aggregation under shear flowconditions. In an ex vivo thrombosis model, inhibition of FXI/FXIa leadsto a significant reduction of platelet activation markers like CD62P aswell as to the reduction of downstream microaggregates in whole bloodunder physiologic flow conditions over a collagen surface. Accordingly,inhibition of FXIa reduces platelet-deposition without compromisingplatelet-dependent primary hemostasis in a primate model ofplatelet-dependent arterial-type thrombus formation. Despite of thepronounced antiplatelet effect, the initial interaction of plateletswith the extravascular matrix proteins that is necessary for the tissuefactor-dependent primary hemostatic plug formation is surprisingly notaffected. Therefore, inhibition of FXI/FXIa activity represents an idealpharmacological principle exhibiting antithrombotic activity withoutcausing bleeding-related side effects. For clarification: Withoutcompromising hemostasis means that the inhibition of the coagulationfactor XI and/or XIa does not lead to unwanted and measurable bleedingevents even in the presence of other anti-coagulation compounds and/oranti-platelet compounds. Like as shown for Hemophilia C patients,bleeding occurs only in the context of intensive surgeries and/or severeinjuries.

Compositions and methods are provided for showing that antibodies orantigen-binding fragments, or variants thereof directed against thecoagulation factor XI in form of its zymogen and/or its activated form,the coagulation factor XIa, exhibit anti-platelet activity by inhibitingor reducing the aggregation of platelets and by this inhibiting orreducing the generation of microagregates and/or thrombotic clots.

Using these anti-coagulation factor XI antibodies and/oranti-coagulation factor XIa antibodies, antigen-binding antibodyfragments, and variants of the antibodies and fragments of theinvention, inhibit platelet aggregation and by this inhibit thrombosiswithout compromising hemostasis.

It is also described herein that the administration of theanti-coagulation factor XI antibodies and/or anti-coagulation factor XIaantibodies are neutralizing antibodies, and that these antibodies,antigen-binding antibody fragments, and variants of the antibodies andfragments of the invention, in order to as an anti-coagulant,anti-thrombotic therapy does not lead to an increased risk of unwantedbleeding events.

The present invention provides human monoclonal antibodies capable ofselectively binding to the activated form of plasma factor XI, FXIa, andthereby inhibiting platelet aggregation and associated thrombosiswithout compromising hemostasis.Compositions include anti-coagulationfactor XI antibodies and/or anti-coagulation factor XIa antibodies arecapable of binding to defined epitopes of the heavy chain of thecoagulation factor XI and/or the light chain of the coagulation factorXIa. These antibodies exhibit neutralizing activity by either/andblocking the proteolytic activity of the coagulation factor XIa and/orby the inhibition of the conversion of the coagulation factor XI to itsactivated form, the coagulation factor XIa via the coagulation factorsFXIlla and/or Thrombin. In a preferred embodiment the invention furtherincludes the cross reactivity of the antibodies to the coagulationfactor XI and/or XIa from other species than human, mainly from rabbit,allowing an in depth pharmacological and toxicological analysis.

In another preferred embodiment methods are used to optimize and reducethe immunogenicity of the compositions of the present invention toreduce the risk of the development of anti-drug antibodies.

The present invention further comprises human antibodies competing withone of the antibodies described herein.

Additionally, compositions include antigen-binding antibody fragments,and variants of the antibodies and fragments of the invention, celllines producing these antibodies, and isolated nuclei acids encoding theamino acids of these antibodies. The invention includes alsopharmaceutical compositions comprising the anti-coagulation factor XIand/or anti-coagulation factor XIa antibodies, or antigen-bindingantibody fragments, and variants of the antibodies and fragments of theinvention, in a pharmaceutically acceptable carrier and/or solution.

Methods of this invention comprise administering the compositionsdescribed above to a subject in need for the purpose of inhibitingplatelet aggregation and by this inhibiting thrombosis, reducing arequired dose of any other anti-coagulant or anti-thrombotic agent inthe treatment of thrombosis, treating an acute inflammatory reaction, ortreating cancer, or treating any other disease associated with theactivation of the coagulation cascade.

Methods for generating anti-coagulation factor XI and/or anti-FXIaantibodies, or antigen-binding antibody fragments, and variants of theantibodies and fragments of the invention, are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1:

Dose-response curves (EC50 is identical to IC50) of anti-FXIa antibody076D-M007-H04 comprising SEQ ID NO: 19 for the amino acid sequence forthe variable light chain domain and SEQ ID NO: 20 for the amino acidsequence for the variable heavy chain domain inhibiting human FXIa. Thisantibody comprise as CDRH1 SEQ ID NO: 21, as CDRH2 SEQ ID NO: 22 and asCDRH3 SEQ ID NO: 23. This antibody further comprise as CDRL1 SEQ ID NO:24, as CDRL2 SEQ ID NO: 25 and as CDRL3 SEQ ID NO: 26. The antibodyidentified in the panning/screening campaign was tested at the indicatedconcentrations for its ability to inhibit the proteolytic activity ofhuman FXIa. The related DNA sequences are shown as SEQ ID NO: 1 to SEQID NO: 8.

FIG. 2:

Dose-response curves of anti-FXIa antibody 076D-M007-H04 inhibitingrabbit FXIa. The antibody identified in the panning/screening campaignwas tested at the indicated concentrations for its ability to inhibitthe proteolytic activity of rabbit FXIa.

FIG. 3:

Dose-response curves of anti-FXIa antibody 076D-M007-H04-CDRL3-N110Dcomprising SEQ ID NO: 27 for the amino acid sequence for the variablelight chain domain and SEQ ID NO: 28 for the amino acid sequence for thevariable heavy chain domain inhibiting human FXIa. The antibodyidentified in the panning/screening campaign was tested at the indicatedconcentrations for its ability to inhibit the proteolytic activity ofhuman FXIa.

FIG. 4:

Dose-response curves of anti-FXIa antibody 076D-M007-H04-CDRL3-N110D.The antibody identified in the panning/screening campaign was tested atthe indicated concentrations for its ability to inhibit the proteolyticactivity of rabbit FXIa.

FIG. 5:

Dose-response curves of anti-FXI antibody 076D-M028-H17 comprising SEQID NO: 29 for the amino acid sequence for the variable light chaindomain and SEQ ID NO: 30 for the amino acid sequence for the variableheavy chain domain inhibiting the conversion human FXI to FXIa by thecoagulation factor XIIa. This antibody comprise as CDRH1 SEQ ID NO: 31,as CDRH2 SEQ ID NO: 32 and as CDRH3 SEQ ID NO: 33. This antibody furthercomprise as CDRL1 SEQ ID NO: 34, as CDRL2 SEQ ID NO: 35 and as CDRL3 SEQID NO: 36. The antibody identified in the panning/screening campaign wastested at the indicated concentrations for their ability to inhibit theconversion of the zymogen FXI into its activated form FXIa. The relatedDNA sequences are shown as SEQ ID NO: 11 to SEQ ID NO: 18.

FIG. 6:

Dose-response curves of anti-FXI antibody 076D-M028-H17 of inhibitingthe conversion human FXI to FXIa by the coagulation factor IIa. Theantibody identified in the panning/screening campaign was tested at theindicated concentrations for their ability to inhibit the conversion ofthe zymogen FXI into its activated form FXIa.

FIG. 7:

Dose-response curves of anti-FXI antibody 076D-M028-H17 of inhibitingthe conversion rabbit FXI to FXIa by the coagulation factor XIIa. Theantibody identified in the panning/screening campaign was tested at theindicated concentrations for their ability to inhibit the conversion ofthe zymogen FXI into its activated form FXIa.

FIG. 8:

Dose-response curves of anti-FXI antibody 076D-M028-H17 of inhibitingthe conversion rabbit FXI to FXIa by the coagulation factor IIa. Theantibody identified in the panning/screening campaign was tested at theindicated concentrations for their ability to inhibit the conversion ofthe zymogen FXI into its activated form FXIa.

FIG. 9:

Binding and blocking activity of 076D-M007-H04 to the catalytic domainof human FXIa. Whereas 076D-M007-H04 inhibits the proteolytic activityof human FXIa, 076D-M028-H17 does not exhibit such an activity,indicating that 076D-M007-H04 binds to the catalytic domain of FXIa.

FIG. 10:

Characterization of the binding modus of 076D-M007-H04 using theLineweaver-Burk plot shows that this antibody exhibits a competitivetype inhibition activity.

FIGS. 11A-B:

Flow cytometric analysis for CD62P expression and plateletmicroaggregate formation. Single platelets were detected by thecombination of light scattering and FITC-CD41/CD61 (GPIIbIIIa)fluorescence. (FIG. 11A) Determination of CD62P expression by a dot plotwith FITC-CD41 and PE-CD62P fluorescence. Gated platelets before (left)and after (right) perfusion are shown. (FIG. 11B) Plateletmicroaggregate formation was defined with the increased size (forwardscatter), indicated in the circle. Dot plots of samples collected before(left) and after (right) perfusion are shown.

FIGS. 12A-B:

Platelet CD62P expression was reduced by FXI(a) antibodies. Whole bloodwas treated with (FIG. 12A) 076D-M007-H04 and (FIG. 12B) 076D-M028-H17and perfused over collagen-coated surface immediately afterrecalcification. In parallel, whole blood samples were collected aftertreatment with vehicle or inhibitor, and incubated with or without TRAP6(10 μg/ml) for 5 min. Platelet CD62P expression was analyzed by flowcytometry as shown in FIG. 11. Data are reported as mean±SEM percentageof CD62P-positive platelets in gated population of at least 5experiments. The maximum CD62P expression levels during 5 min perfusionin each treatment are shown in the graphs.

FIGS. 13A-B:

Platelet microaggregate formation was inhibited by FXI(a) antibodies.

Whole blood was treated with (FIG. 13A) 076D-M007-H04 and (FIG. 13B)076D-M028-H17 and perfused over collagen-coated surface immediatelyafter recalcification. Platelet microaggregates were analyzed by flowcytometry as shown in FIG. 13 and represented as. Data are reported asmean±SEM aggregate count versus 10⁴ gated single platelets of at least 5experiments. The maximum aggregate counts during 5 min perfusion in eachtreatment are shown in the graphs.

FIGS. 14A-B:

In vivo effect of 076D-M007-H04 on ferric chloride induced thrombosis(FIG. 14A) and on ear bleeding time (FIG. 14B). It could be demonstratedthat 076D-M007-H04 dose-dependently reduces the thrombus weight withoutincreasing the ear bleeding time.

FIGS. 15A-B:

In vivo effect of 076D-M007-H04-CDRL3-N110D on ferric chloride inducedthrombosis (FIG. 15A) and on ear bleeding time (FIG. 15B) (described inexample xxx). It could be demonstrated that 076D-M007-H04-CDRL3-N110Ddose-dependently reduces the thrombus weight without increasing the earbleeding time.

FIGS. 16A-B:

In vivo effect shows the effect of 076D-M028-H17 on ferric chlorideinduced thrombosis (FIG. 16A) and on ear bleeding time (FIG. 16B)(described in example xxx). It could be demonstrated that 076D-M028-H17dose-dependently reduces the thrombus weight without increasing the earbleeding time.

FIG. 17:

This figure depicts a cartoon representation of the Fab 076D-M007-H04(lower part) in complex with FXIa (upper part).

FIG. 18A:

This figure depicts—a detailed view into the binding epitope of Fab076D-M007-H04 (cartoon) to FXIa C500S. FXIa C500S is shown as surfacerepresentation.

FIG. 18B:

This figure shows Fab 076D-M007-H04 with a superimposed peptidic x-raystructure of FXIa C500S shown as surface representation. The active sitecleft is highlighted with a red ellipsoid.

FIG. 19A:

This figure depicts the crystal structure of zymogen FXI (odb entry2F83) with superimposed Fab 076D-M007-H04.

FIG. 19B:

This figure depicts the same view but the catalytic domain of FXI ofzymogen is replaced by catalytic domain of FXIa C500S of the complexstructure of Fab 076D-M007-H04:FXIa C500S. The catalytic domains of FXIand FXIa C500S are shown as surface represenations, all other domainsare shown as cartoons. The not properly ordered loops at the interfaceto Fab 076D-M007-H04 are highlighted in FIG. 19.

FIG. 20:

Increase in in vitro aPTT clotting time determined in plasma samplescollected from baboons following 076D-M007-H04 administration.

FIG. 21:

ACT measurements following 2.5 mg/kg 076D-M007-H04 administration (i.v.bolus) from 5 minutes post-dose through 504 hours post-dose.

FIG. 22:

The first 24 hours of ACT measurements following 2.5 mg/kg 076D-M007-H04administration (i.v. bolus).

FIG. 23:

aPTT measurements following 2.5 mg/kg 076D-M007-H04 administration (i.v.bolus) from 5 minutes post-dose through 504 hours post-dose.

FIG. 24:

The first 24 hours of aPTT measurements following 2.5 mg/kg076D-M007-H04 administration (i.v. bolus).

FIG. 25:

Platelet deposition in 2 mm i.d. collagen-coated ePTFE vascular grafts.

FIG. 26:

Platelet deposition on collagen-coated ePTFE vascular grafts asdescribed in Example 12.

FIG. 27:

Platelet deposition in the venous expansion chamber (and in the linkersection between the collagen-coated graft and the silicon chamber) asdescribed under the section Example 12.

FIG. 28:

TAT levels measured in baboon plasma following 076D-M007-HO4administration.

FIG. 29:

Bleeding time in baboons treated with 0.5 mg/kg 076D-M007-H04 and 2mg/kg 076D-M007-H04 (24 hours later) alone or after they were givenchewable aspirin at a concentration of 32 mg/kg.

DETAILED DESCRIPTION OF THE INVENTION Definitions

Hemostasis: The term hemostasis represents the principal mechanisms forarresting the flow of blood at sites of injury and restoring vascularpatency during wound healing, respectively. During normal hemostasis andpathological thrombosis, three mechanisms become activatedsimultaneously: primary hemostasis meaning the interactions of activatedplatelets with the vessel wall, the formation of fibrin, and a processtermed as fibrinolysis [Arthur A. Sasahara, Joseph Loscalzo (2002) NewTherapeutic Agents for Thrombosis and Thrombolysis (2nd Edition) MarcelDekker Inc. New York, N.Y., ISBN 0-8247-0795-8].

Coagulation and Coagulation cascade: The protein based system termedcoagulation cascade serves to stabilize the clot that has formed andfurther seal up the wound. The coagulation pathway is a proteolyticcascade. Each enzyme of the pathway is present in the plasma as aZymogen (in an inactive form), which on activation undergoes proteolyticcleavage to release the active factor from the precursor molecule. Thecoagulation cascade functions as a series of positive and negativefeedback loops which control the activation process. The ultimate goalof the pathway is to produce Thrombin, which can then convert solubleFibrinogen into Fibrin that forms a clot. The process of generation ofThrombin can be divided into three phases: the Intrinsic and Extrinsicpathways which provide alternative routes for the generation of anactive clotting factor: FXa (Activated Factor-X), and the final Commonpathway which results in Thrombin formation [Hoffman M. M. and Monroe D.M. (2005) Rethinking the coagulation cascade. Curr Hematol Rep.4:391-396; Johne J, Blume C, Benz P M, Pozgajová M, Ullrich M, Schuh K,Nieswandt B, Walter U, Renné T. (2006) Platelets promote coagulationfactor XII-mediated proteolytic cascade systems in plasma. Biol Chem.387:173-178].

Platelet aggregation: When a break in a blood vessel occurs, substancesare exposed that normally are not in direct contact with the blood flow.These substances (primarily Collagen and von Willebrand factor) allowthe platelets to adhere to the broken surface. Once a platelet adheresto the surface, it releases chemicals that attract additional plateletsto the damaged area, referred to as platelet aggregation. These twoprocesses are the first responses to stop bleeding.

Coagulation Factor XI and Coagulation Factor XIa

The coagulation Factor XI (FXI) is synthesized in the liver andcirculates in the plasma as a disulfide bond-linked dimer complexed withHigh Molecular Weight Kininogen. Each polypeptide chain of this dimer isapproximately 80 kD. The zymogen Factor XI is converted into its activeform, the coagulation factor XIa (FXIa) either via the contact phase ofblood coagulation or through Thrombin-mediated activation on theplatelet surface. During this activation of factor XI, an internalpeptide bond is cleaved in each of the two chains, resulting in theactivated factor XIa, a serine protease composed of two heavy and twolight chains held together by disulfide bonds. This serine protease FXIaconverts the coagulation Factor IX into IXa, which subsequentlyactivates coagulation Factor X (Xa). Xa then can mediate coagulationFactor II/Thrombin activation. Defects in this factor lead to Rosenthalsyndrome (also known as hemophilia C), a blood coagulation abnormalitycharacterized by prolonged bleeding from injuries, frequent or heavynosebleeds, traces of blood in the urine, and heavy menstrual bleedingin females. As used herein, “coagulation factor XI,” “factor XI”, or“FXI” refers to any FXI from any mammalian species that expresses theprotein. For example, FXI can be human, non-human primate (such asbaboon), mouse, dog, cat, cow, horse, pig, rabbit, and any other speciesexhibiting the coagulation factor XI involved in the regulation of bloodflow, coagulation, and/or thrombosis.

The cleavage site for the activation of the coagulation factor XI by thecoagulation factor XIIa is an internal peptide bond between Arg-369 andIle-370 in each polypeptide chain [Fujikawa K, Chung D W, Hendrickson LE, Davie E W. (1986) Amino acid sequence of human factor XI, a bloodcoagulation factor with four tandem repeats that are highly homologouswith plasma prekallikrein. Biochemistry 25:2417-2424]. Each heavy chainof the coagulation factor XIa (369 amino acids) contains four tandemrepeats of 90-91 amino acids called apple domains (designated A1-A4)plus a short connecting peptide [Fujikawa K, Chung D W, Hendrickson L E,Davie E W. (1986) Amino acid sequence of human factor X I, a bloodcoagulation factor with four tandem repeats that are highly homologouswith plasma prekallikrein. Biochemistry 25:2417-2424; Sun M F, Zhao M,Gailani D. (1999) Identification of amino acids in the factor XI apple 3domain required for activation of factor IX. J Biol Chem.274:36373-36378]. The light chains of the coagulation factor XIa (each238 amino acids) contain the catalytic portion of the enzyme withsequences that are typical of the trypsin family of serine proteases[Fujikawa K, Chung D W, Hendrickson L E, Davie E W. (1986) Amino acidsequence of human factor XI, a blood coagulation factor with four tandemrepeats that are highly homologous with plasma prekallikrein.Biochemistry 25:2417-2424]. Activated factor XIa triggers the middlephase of the intrinsic pathway of blood coagulation by activating factorIX.

Conservative Amino Acid Variants

Polypeptide variants may be made that conserve the overall molecularstructure of an antibody peptide sequence described herein. Given theproperties of the individual amino acids, some rational substitutionswill be recognized by the skilled worker. Amino acid substitutions,i.e., “conservative substitutions,” may be made, for instance, on thebasis of similarity in polarity, charge, solubility, hydrophobicity,hydrophilicity, and/or the amphipathic nature of the residues involved.

For example, (a) nonpolar (hydrophobic) amino acids include alanine,leucine, isoleucine, valine, proline, phenylalanine, tryptophan, andmethionine; (b) polar neutral amino acids include glycine, serine,threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positivelycharged (basic) amino acids include arginine, lysine, and histidine; and(d) negatively charged (acidic) amino acids include aspartic acid andglutamic acid. Substitutions typically may be made within groups(a)-(d). In addition, glycine and proline may be substituted for oneanother based on their ability to disrupt α-helices. Similarly, certainamino acids, such as alanine, cysteine, leucine, methionine, glutamicacid, glutamine, histidine and lysine are more commonly found inα-helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophanand threonine are more commonly found in β-pleated sheets. Glycine,serine, aspartic acid, asparagine, and proline are commonly found inturns. Some preferred substitutions may be made among the followinggroups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given theknown genetic code, and recombinant and synthetic DNA techniques, theskilled scientist readily can construct DNAs encoding the conservativeamino acid variants.

As used herein, “sequence identity” between two polypeptide sequences,indicates the percentage of amino acids that are identical between thesequences. “Sequence homology” indicates the percentage of amino acidsthat either is identical orthat represent conservative amino acidsubstitutions. Preferred polypeptide sequences of the invention have asequence identity in the CDR regions of at least 60%, more preferably,at least 70% or 80%, still more preferably at least 90% and mostpreferably at least 95%. Preferred antibodies also have a sequencehomology in the CDR regions of at least 80%, more preferably 90% andmost preferably 95%.

DNA Molecules of the Invention

The present invention also relates to the DNA molecules that encode anantibody of the invention. These sequences include, but are not limitedto, those DNA molecules set forth in SEQ ID NOs 1 to 18.

DNA molecules of the invention are not limited to the sequencesdisclosed herein, but also include variants thereof. DNA variants withinthe invention may be described by reference to their physical propertiesin hybridization. The skilled worker will recognize that DNA can be usedto identify its complement and, since DNA is double stranded, itsequivalent or homolog, using nucleic acid hybridization techniques. Italso will be recognized that hybridization can occur with less than 100%complementarity. However, given appropriate choice of conditions,hybridization techniques can be used to differentiate among DNAsequences based on their structural relatedness to a particular probe.For guidance regarding such conditions see, Sambrook et al., 1989[Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning:A laboratory manual, Cold Spring Harbor Laboratory Press, Cold SpringHarbor, USA)] and Ausubel et al., 1995 [Ausubel, F. M., Brent, R.,Kingston, R. E., Moore, D. D., Sedman, J. G., Smith, J. A., & Struhl, K.eds. (1995). Current Protocols in Molecular Biology. New York: JohnWiley and Sons].

Structural similarity between two polynucleotide sequences can beexpressed as a function of “stringency” of the conditions under whichthe two sequences will hybridize with one another. As used herein, theterm “stringency” refers to the extent that the conditions disfavorhybridization. Stringent conditions strongly disfavor hybridization, andonly the most structurally related molecules will hybridize to oneanother under such conditions. Conversely, non-stringent conditionsfavor hybridization of molecules displaying a lesser degree ofstructural relatedness. Hybridization stringency, therefore, directlycorrelates with the structural relationships of two nucleic acidsequences. The following relationships are useful in correlatinghybridization and relatedness (where T_(m) is the melting temperature ofa nucleic acid duplex):

-   a. T_(m)=69.3+0.41(G+C) %-   b. The T_(m) of a duplex DNA decreases by 1° C. with every increase    of 1% in the number of mismatched base pairs.-   c. (T_(m))_(μ2)−(T_(m))_(μ1)=18.5 log₁₀μ2/μ1    -   where μ1 and μ2 are the ionic strengths of two solutions.

Hybridization stringency is a function of many factors, includingoverall DNA concentration, ionic strength, temperature, probe size andthe presence of agents which disrupt hydrogen bonding. Factors promotinghybridization include high DNA concentrations, high ionic strengths, lowtemperatures, longer probe size and the absence of agents that disrupthydrogen bonding. Hybridization typically is performed in two phases:the “binding” phase and the “washing” phase.

First, in the binding phase, the probe is bound to the target underconditions favoring hybridization. Stringency is usually controlled atthis stage by altering the temperature. For high stringency, thetemperature is usually between 65° C. and 70° C., unless short (<20 nt)oligonucleotide probes are used. A representative hybridization solutioncomprises 6×SSC, 0.5% SDS, 5×Denhardt's solution and 100 μg ofnonspecific carrier DNA [see 15]. Of course, many different, yetfunctionally equivalent, buffer conditions are known. Where the degreeof relatedness is lower, a lower temperature may be chosen. Lowstringency binding temperatures are between about 25° C. and 40° C.Medium stringency is between at least about 40° C. to less than about65° C. High stringency is at least about 65° C.

Second, the excess probe is removed by washing. It is at this phase thatmore stringent conditions usually are applied. Hence, it is this“washing” stage that is most important in determining relatedness viahybridization. Washing solutions typically contain lower saltconcentrations. One exemplary medium stringency solution contains 2×SSCand 0.1% SDS. A high stringency wash solution contains the equivalent(in ionic strength) of less than about 0.2×SSC, with a preferredstringent solution containing about 0.1×SSC. The temperatures associatedwith various stringencies are the same as discussed above for “binding.”The washing solution also typically is replaced a number of times duringwashing. For example, typical high stringency washing conditionscomprise washing twice for 30 minutes at 55° C. and three times for 15minutes at 60° C.

Accordingly, subject of the present invention is an isolated nucleicacid sequence that encodes the antibody and/or antigen-binding fragmentsof the present invention. Another embodiment of the present invention isthe afore mentioned isolated nucleic acid sequence, which encodes theantibodies of the present invention. Accordingly, the present inventionincludes nucleic acid molecules that hybridize to the molecules of setforth under high stringency binding and washing conditions, where suchnucleic molecules encode an antibody or functional fragment thereofhaving properties as described herein. Preferred molecules (from an mRNAperspective) are those that have at least 75% or 80% (preferably atleast 85%, more preferably at least 90% and most preferably at least95%) sequence identity with one of the DNA molecules described herein.The DNA codes for molecules which reduce and or inhibit the conversionof the coagulation factor XI into its active form factor XIa and/orblock the catalytic activity of the coagulation factor XIa directly.

Recombinant DNA Constructs and Expression

The present invention further provides recombinant DNA constructscomprising one or more of the nucleotide sequences of the presentinvention. The recombinant constructs of the present invention are usedin connection with a vector, such as a plasmid, phagemid, phage or viralvector, into which a DNA molecule encoding an antibody of the inventionis inserted. The encoded gene may be produced by techniques described inSambrook et al., 1989, and Ausubel et al., 1989. [Sambrook, J., Fritsch,E. F. and Maniatis, T. (1989) Molecular Cloning: A laboratory manual,Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA; Ausubel,F. M., Brent, R., Kingston, R. E., Moore, D. D., Sedman, J. G., Smith,J. A., & Struhl, K. eds. (1995). Current Protocols in Molecular Biology.New York: John Wiley and Sons]. Alternatively, the DNA sequences may bechemically synthesized using, for example, synthesizers. See, forexample, the techniques described in OLIGONUCLEOTIDE SYNTHESIS [Gait, M.J. (1984) “An introduction to modern methods of DNA Synthesis” InOligonucleotide Synthesis a Practical Approach. Ed. M. J. Gait, IRLPress Oxford UK] which is incorporated by reference herein in itsentirety. The expert in the field is able to fuse DNA encoding thevariable domains with gene fragments encoding constant regions ofvarious human IgG isotypes or derivatives thereof, either mutated ornon-mutated. He is able to apply recombinant DNA technology in order tofuse both variable domains in a single chain format using linkers suchas a fifteen-amino acid stretch containing three timesglycine-glycine-glycine-glycine-serine. Recombinant constructs of theinvention are comprised with expression vectors that are capable ofexpressing the RNA and/or protein products of the encoded DNA(s). Thevector may further comprise regulatory sequences, including a promoteroperably linked to the open reading frame (ORF). The vector may furthercomprise a selectable marker sequence. Specific initiation and bacterialsecretory signals also may be required for efficient translation ofinserted target gene coding sequences.

The present invention further provides host cells containing at leastone of the DNAs of the present invention. The host cell can be virtuallyany cell for which expression vectors are available. It may be, forexample, a higher eukaryotic host cell, such as a mammalian cell, alower eukaryotic host cell, such as a yeast cell, and may be aprokaryotic cell, such as a bacterial cell. Introduction of therecombinant construct into the host cell can be effected by calciumphosphate transfection, DEAE, dextran mediated transfection,electroporation or phage infection.

Bacterial Expression

Useful expression vectors for bacterial use are constructed by insertinga structural DNA sequence encoding a desired protein together withsuitable translation initiation and termination signals in operablereading phase with a functional promoter. The vector will comprise oneor more phenotypic selectable markers and an origin of replication toensure maintenance of the vector and, if desirable, to provideamplification within the host. Suitable prokaryotic hosts fortransformation include E. coli, Bacillus subtilis, Salmonellatyphimurium and various species within the genera Pseudomonas,Streptomyces, and Staphylococcus.

Bacterial vectors may be, for example, bacteriophage-, plasmid- orphagemid-based. These vectors can contain a selectable marker andbacterial origin of replication derived from commercially availableplasmids typically containing elements of the well known cloning vectorpBR322 (ATCC 37017). Following transformation of a suitable host strainand growth of the host strain to an appropriate cell density, theselected promoter is de-repressed/induced by appropriate means (e.g.,temperature shift or chemical induction) and cells are cultured for anadditional period. Cells are typically harvested by centrifugation,disrupted by physical or chemical means, and the resulting crude extractretained for further purification.

In bacterial systems, a number of expression vectors may beadvantageously selected depending upon the use intended for the proteinbeing expressed. For example, when a large quantity of such a protein isto be produced, for the generation of antibodies or to screen peptidelibraries, for example, vectors which direct the expression of highlevels of fusion protein products that are readily purified may bedesirable.

Therefore an object of the present invention is an expression vectorcomprising a nucleic acid sequence encoding for the novel antibodies ofthe present invention.

Mammalian Expression and Protein Purification

Preferred regulatory sequences for mammalian host cell expressioninclude viral elements that direct high levels of protein expression inmammalian cells, such as promoters and/or enhancers derived fromcytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., theadenovirus major late promoter (AdMLP)) and polyoma. For furtherdescription of viral regulatory elements, and sequences thereof [seeU.S. Pat. No. 5,168,062 by Stinski; U.S. Pat. No. 4,510,245 by Bell etal.; U.S. Pat. No. 4,968,615 by Schaffner et al.]. The recombinantexpression vectors can also include origins of replication andselectable markers [see U.S. Pat. No. 4,510,245 by Bell et al.; U.S.Pat. No. 4,968,615 by Schaffner et al.; U.S. Pat. No. 4,399,216, by Axelet al.] Suitable selectable markers include genes that confer resistanceto drugs such as G418, hygromycin or methotrexate, on a host cell intowhich the vector has been introduced. For example, the dihydrofolatereductase (DHFR) gene confers resistance to methotrexate and the neogene confers resistance to G418.

Transfection of the expression vector into a host cell can be carriedout using standard techniques such as electroporation, calcium-phosphateprecipitation, and DEAE-dextran transfection.

Suitable mammalian host cells for expressing the antibodies, antigenbinding portions, or derivatives thereof provided herein include ChineseHamster Ovary (CHO cells) [including dhfr− CHO cells, described in [U.S.Pat. No. 4,634,665 by Axel et al.] used with a DHFR selectable marker,e.g., as described in [U.S. Pat. No. 5,179,017, by Axel et al.]. NSOmyeloma cells, COS cells and SP2 cells. In some embodiments, theexpression vector is designed such that the expressed protein issecreted into the culture medium in which the host cells are grown.

The antibodies, antigen binding portions, or derivatives thereof can berecovered from the culture medium using standard protein purificationmethods.

Antibodies of the invention or an antigen-binding fragment thereof canbe recovered and purified from recombinant cell cultures by well-knownmethods including, but not limited to ammonium sulfate or ethanolprecipitation, acid extraction, Protein A chromatography, Protein Gchromatography, anion or cation exchange chromatography,phospho-cellulose chromatography, hydrophobic interactionchromatography, affinity chromatography, hydroxylapatite chromatographyand lectin chromatography. High performance liquid chromatography(“HPLC”) can also be employed for purification [see Urlaub G, Chasin LA. (1980) Isolation of Chinese hamster cell mutants deficient indihydrofolate reductase activity. Proc Natl Acad Sci USA. 77:4216-4220;e.g chapters 1, 4, 6, 8, 9, 10, each entirely incorporated herein byreference]. Antibodies of the present invention or antigen-bindingfragment thereof include naturally purified products, products ofchemical synthetic procedures, and products produced by recombinanttechniques from a eukaryotic host, including, for example, yeast, higherplant, insect and mammalian cells. Depending upon the host employed in arecombinant production procedure, the antibody of the present inventioncan be glycosylated or can be non-glycosylated. Such methods aredescribed in many standard laboratory manuals [see Sambrook, J.,Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A laboratorymanual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA);Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Sedman, J. G.,Smith, J. A., & Struhl, K. eds. (1995). Current Protocols in MolecularBiology. New York: John Wiley and Sons, chapters 10, 12, 13, 16, 18 and20]. Therefore an object of the present invention are also host cellscomprising the vector or a nucleic acid molecule, whereby the host cellcan be a higher eukaryotic host cell, such as a mammalian cell, a lowereukaryotic host cell, such as a yeast cell, and may be a prokaryoticcell, such as a bacterial cell.

Another object of the present invention is a method of using the hostcell to produce an antibody and antigen binding fragments, comprisingculturing the host cell under suitable conditions and recovering saidantibody.

Therefore another object of the present invention is the antibody005-C04 produced with the host cells of the present invention andpurified to at least 95% homogeneity by weight.

Affinity

“Affinity” or “binding affinity” K_(D) are often determined bymeasurement of the equilibrium association constant (ka) and equilibriumdissociation constant (kd) and calculating the quotient of kd to ka(K_(D)=kd/ka). The term “immunospecific” or “specifically binding” meansthat the antibody binds to the coagulation factor XI and/or itsactivated form, the coagulation factor XIa with an affinity K_(D) oflower than or equal to 10⁻⁶M (monovalent affinity). The term “highaffinity” means that the _(KD) that the antibody binds to thecoagulation factor XI and/or its activated form, the coagulation factorXIa with an affinity K_(D) of lower than or equal to 10⁻⁷M (monovalentaffinity). The antibody may have substantially greater affinity for thetarget antigen compared to other unrelated molecules. The antibody mayalso have substantially greater affinity for the target antigen comparedto homologs, e.g. at least 1.5-fold, 2-fold, 5-fold 10-fold, 100-fold,10⁻³-fold, 10⁻⁴-fold, 10⁻⁵-fold, 10⁻⁶-fold or greater relative affinityfor the target antigen. Such affinities may be readily determined usingconventional techniques, such as by equilibrium dialysis; by using theBIAcore 2000 instrument, using general procedures outlined by themanufacturer; by radioimmunoassay using radiolabeled target antigen; orby another method known to the skilled artisan. The affinity data may beanalyzed, for example, by the method described in [Kaufman R J, Sharp PA. (1982) Amplification and expression of sequences cotransfected with amodular dihydrofolate reductase complementary dna gene. J Mol Biol.159:601-621].

Antibodies

As used herein the phrase “antibodies blocking the coagulation FXIand/or its activated form, the coagulation factor XIa” is meant to referto a blockade of FXI and/or FXIa by the antibodies of the presentinvention which leads to a complete or partial inhibition of thecoagulation factor FXI and/or FXIa activity. The amino acid sequencesinclude, but are not limited to, those DNA molecules set forth in SEQ IDNOs 19 to 36.

The term “antibody” is used in the broadest sense and includes fullyassembled antibodies, monoclonal antibodies, polyclonal antibodies,multispecific antibodies (e.g., bispecific antibodies), antibodyfragments that can bind the antigen (e.g., Fab′, F′(ab)2, Fv, singlechain antibodies, diabodies), camel bodies and recombinant peptidescomprising the forgoing as long as they exhibit the desired biologicalactivity. Antibodies may carry different constant domains (Fc domains)on their heavy chain preferably derived from IgG1, IgG2, or IgG4isotypes (see below). Mutations for modification of effector functionsmay be introduced. Amino acid residues in the Fc-domain that play adominant role in the interactions with the complement protein Clq andthe Fc receptors have been identified and mutations influencing effectorfunctions have been described [for a review see Colligan, CurrentProtocols in Immunology, or Current Protocols in Protein Science, JohnWiley & Sons, NY, N.Y., (1997-2001)] Particularly, aglycosylation ofIgG1 may be achieved by mutating asparagine to alanine or asparagine toglutamine at amino acid position 297, which has been reported to abolishantibody-derived cell-mediated cytotoxicity (ADCC) [Labrijn A F,Aalberse R C, Schuurman J. (2008) When binding is enough: nonactivatingantibody formats. Curr Opin Immunol. 20:479-485]. Replacement of lysineby alanine at position 322 leads to reduction of ADCC and removal ofcomplement-derived cytotoxicity (CDC), while simultaneous replacement ofthe two leucines at position 234 and 235 by alanines leads to avoidanceof ADCC and CDC [Sazinsky S L, Ott R G, Silver N W, Tidor B, Ravetch JV, Wittrup K D. (2008) Aglycosylated immunoglobulin G1 variantsproductively engage activating Fc receptors. Proc Natl Acad Sci USA.105:20167-20172] In order to apply IgG4 isotypes as bivalenttherapeutics in vivo which retain avidity, a modification such as theserine-to-proline exchange in the ‘core hinge region’ [Schuurman J, VanRee R, Perdok G J, Van Doorn H R, Tan K Y, Aalberse R C. (1999) Normalhuman immunoglobulin G4 is bispecific: it has two differentantigen-combining sites. Immunology. 97:693-698] may be introduced. Thetendency of human IgG2 molecules to form heterogeneous covalent dimersmay be circumvented by exchanging one of the cysteines at position 127,232 and 233 to serine [Simmons L C, Reilly D, Klimowski L, Raju T S,Meng G, Sims P, Hong K, Shields R L, Damico L A, Rancatore P, Yansura DG. (2002) Expression of full-length immunoglobulins in Escherichia coli:rapid and efficient production of aglycosylated antibodies. J ImmunolMethods. 263:133-147]. An alternative format with reduced effectorfunction may be the IgG2m4 format, derived from IgG2 carrying fourIgG4-specific amino acid residue changes [Hezareh M, Hessell A J, JensenR C, van de Winkel J G, Parren P W. (2001) Effector function activitiesof a panel of mutants of a broadly neutralizing antibody against humanimmunodeficiency virus type 1. J Virol. 75:12161-1218]. Antibodyfragments may be produced by recombinant DNA techniques or by enzymaticor chemical cleavage of intact antibodies and are described furtherbelow. Nonlimiting examples of monoclonal antibodies include murine,chimeric, humanized, human, and Human Engineered™ immunoglobulins,antibodies, chimeric fusion proteins having sequences derived fromimmunoglobulins, or muteins or derivatives thereof, each describedfurther below. Multimers or aggregates of intact molecules and/orfragments, including chemically derivatized antibodies, arecontemplated.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,i.e., the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations that may be present inminor amounts. Monoclonal antibodies are highly specific, being directedagainst a single antigenic site. Furthermore, in contrast toconventional (polyclonal) antibody preparations that typically includedifferent antibodies directed against different determinants (epitopes),each monoclonal antibody is directed against a single determinant on theantigen. In addition to their specificity, the monoclonal antibodies areadvantageous in that they are synthesized by the homogeneous culture,uncontaminated by other immunoglobulins with different specificities andcharacteristics.

The modifier “monoclonal” indicates the character of the antibody asbeing obtained from a substantially homogeneous population ofantibodies, and is not to be construed as requiring production of theantibody by any particular method. For example, the monoclonalantibodies to be used may be made by the hybridoma method firstdescribed by Kohler et al. [Allen M J, Guo A, Martinez T, Han M, Flynn GC, Wypych J, Liu Y D, Shen W D, Dillon™, Vezina C, Balland A. (2009)Interchain disulfide bonding in human IgG2 antibodies probed bysite-directed mutagenesis. Biochemistry. 48:3755-3766] or may be made byrecombinant DNA methods [see An Z, Forrest G, Moore R, Cukan M, HaytkoP, Huang L, Vitelli S, Zhao J Z, Lu P, Hua J, Gibson C R, Harvey B R,Montgomery D, Zaller D, Wang F, Strohl W. (2009) IgG2m4, an engineeredantibody isotype with reduced Fc function. MAbs. 1:572-579]. The“monoclonal antibodies” may also be recombinant, chimeric, humanized,human, Human Engineered™, or antibody fragments, for example.

An “immunoglobulin” or “native antibody” is a tetrameric glycoprotein.In a naturally-occurring immunoglobulin, each tetramer is composed oftwo identical pairs of polypeptide chains, each pair having one “light”(about 25 kDa) and one “heavy” chain (about 50-70 kDa). Theamino-terminal portion of each chain includes a “variable” region ofabout 100 to 110 or more amino acids primarily responsible for antigenrecognition. The carboxy-terminal portion of each chain defines aconstant region primarily responsible for effector function.Immunoglobulins can be assigned to different classes depending on theamino acid sequence of the constant domain of their heavy chains. Heavychains are classified as mu (μ), delta (Δ), gamma (γ), alpha (α), andepsilon (ϵ), and define the antibody's isotype as IgM, IgD, IgG, IgA,and IgE, respectively. Several of these may be further divided intosubclasses or isotypes, e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.Different isotypes have different effector functions; for example, IgG1and IgG3 isotypes often have ADCC activity. Human light chains areclassified as kappa (κ) and lambda (λ) light chains. Within light andheavy chains, the variable and constant regions are joined by a “J”region of about 12 or more amino acids, with the heavy chain alsoincluding a “D” region of about 10 more amino acids [see generallyKohler G, Milstein C. (1975) Continuous cultures of fused cellssecreting antibody of predefined specificity. Nature. 256:495-497].

A “functional fragment” or “antigen-binding antibody fragment” of anantibody/immunoglobulin hereby is defined as a fragment of anantibody/immunoglobulin (e.g., a variable region of an IgG) that retainsthe antigen-binding region. An “antigen-binding region” of an antibodytypically is found in one or more hypervariable region(s) of anantibody, ie., the CDR-1, -2, and/or -3 regions; however, the variable“framework” regions can also play an important role in antigen binding,such as by providing a scaffold for the CDRs. Preferably, the“antigen-binding region” comprises at least amino acid residues 4 to 103of the variable light (VL) chain and 5 to 109 of the variable heavy (VH)chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111of VH, and particularly preferred are the complete VL and VH chains[amino acid positions 1 to 109 of VL and 1 to 113 of VH, while numberingof amino acid positions occurs according to the Kabat database [U.S.Pat. No. 4,816,567]. A preferred class of immunoglobulins for use in thepresent invention is IgG.

The term “hypervariable” region refers to the amino acid residues of thevariable domains VH and VL of an antibody or functional fragment whichare responsible for antigen-binding. The hypervariable region comprisesamino acid residues from a “complementarity determining region” or CDR[i.e., residues 24-34 (LCDR1), 50-56 (LCDR2) and 88-97 (LCDR3) in thelight chain variable domain and 29-36 (HCDR1), 48-66 (HCDR2) and 93-102(HCDR3) in the heavy chain variable domain and/or those residues from ahypervariable loop [i.e., residues 26-32 (within LCDR1), 50-52 (withinLCDR2) and 91-96 (within LCDR3) in the light chain variable domain and26-32 (within HCDR1), 53-55 (within HCDR2) and 96-101 (within HCDR3) inthe heavy chain variable domain as described in [Fundamental Immunology,Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)].

Nonlimiting examples of antibody fragments include Fab, Fab′, F(ab′)2,Fv, domain antibody (dAb), complementarity determining region (CDR)fragments, single-chain antibodies (scFv), single chain antibodyfragments, diabodies, triabodies, tetrabodies, minibodies, linearantibodies [Johnson G, Wu T T. (2000) Kabat database and itsapplications: 30 years after the first variability plot. Nucleic AcidsRes. 28:214-218]; chelating recombinant antibodies, tribodies orbibodies, intrabodies, nanobodies, small modular immunopharmaceuticals(SMIPs), an antigen-binding-domain immunoglobulin fusion protein, acamelized antibody, a VHH containing antibody, or muteins or derivativesthereof, and polypeptides that contain at least a portion of animmunoglobulin that is sufficient to confer specific antigen binding tothe polypeptide, such as a CDR sequence, as long as the antibody retainsthe desired biological activity; and multispecific antibodies formedfrom antibody fragments [Chothia C, Lesk A M. (1987) Canonicalstructures for the hypervariable regions of immunoglobulins. J Mol Biol.196:901-917; Zapata G, Ridgway J B, Mordenti J, Osaka G, Wong W L,Bennett G L, Carter P. (1995) Engineering linear F(ab′)2 fragments forefficient production in Escherichia coli and enhanced antiproliferativeactivity. Protein Eng. 8:1057-1062]. An antibody other than a“bispecific” or “bifunctional” antibody is understood to have each ofits binding sites identical. The F(ab′)₂ or Fab may be engineered tominimize or completely remove the intermolecular disulphide interactionsthat occur between the C_(H1) and C_(L) domains. Papain digestion ofantibodies produces two identical antigen-binding fragments, called“Fab” fragments, each with a single antigen-binding site, and a residual“Fc” fragment, whose name reflects its ability to crystallize readily.Pepsin treatment yields an F(ab′)2 fragment that has two “Fv” fragments.An “Fv” fragment is the minimum antibody fragment that contains acomplete antigen recognition and binding site. This region consists of adimer of one heavy- and one light-chain variable domain in tight,non-covalent association. It is in this configuration that the threeCDRs of each variable domain interact to define an antigen binding siteon the surface of the VH-VL dimer. Collectively, the six CDRs conferantigen-binding specificity to the antibody. However, even a singlevariable domain (or half of an Fv comprising only three CDRs specificfor an antigen) has the ability to recognize and bind antigen.

“Single-chain Fv” or “sFv” or “scFv” antibody fragments comprise the VHand VL domains of antibody, wherein these domains are present in asingle polypeptide chain.

Preferably, the Fv polypeptide further comprises a polypeptide linkerbetween the VH and VL domains that enables the Fv to form the desiredstructure for antigen binding. For a review of sFv see [C. A. KBorrebaeck, editor (1995) Antibody Engineering (Breakthroughs inMolecular Biology), Oxford University Press].

The Fab fragment also contains the constant domain of the light chainand the first constant domain (CH1) of the heavy chain. Fab fragmentsdiffer from Fab′ fragments by the addition of a few residues at thecarboxy terminus of the heavy chain CH1 domain including one or morecysteines from the antibody hinge region. Fab′-SH is the designationherein for Fab′ in which the cysteine residue(s) of the constant domainsbear a free thiol group. F(ab′)2 antibody fragments originally wereproduced as pairs of Fab′ fragments which have hinge cysteines betweenthem.

“Framework” or FR residues are those variable domain residues other thanthe hypervariable region residues.

The phrase “constant region” refers to the portion of the antibodymolecule that confers effector functions.

The term “mutein” or “variant” can be used interchangeably and refers tothe polypeptide sequence of an antibody that contains at least one aminoacid substitution, deletion, or insertion in the variable region or theportion equivalent to the variable region, provided that the mutein orvariant retains the desired binding affinity or biological activity.

Muteins may be substantially homologous or substantially identical tothe parent antibody.

The term “derivative” refers to antibodies covalently modified by suchtechniques as ubiquitination, conjugation to therapeutic or diagnosticagents, labeling (e.g., with radionuclides or various enzymes), covalentpolymer attachment such as pegylation (derivatization with polyethyleneglycol) and insertion or substitution by chemical synthesis ofnon-natural amino acids.

A “human” antibody or functional human antibody fragment is herebydefined as one that is not chimeric or “humanized” and not from (eitherin whole or in part) a non-human species. A human antibody or functionalantibody fragment can be derived from a human or can be a synthetichuman antibody. A “synthetic human antibody” is defined herein as anantibody having a sequence derived, in whole or in part, in silico fromsynthetic sequences that are based on the analysis of known humanantibody sequences. In silico design of a human antibody sequence orfragment thereof can be achieved, for example, by analyzing a databaseof human antibody or antibody fragment sequences and devising apolypeptide sequence utilizing the data obtained therefrom. Anotherexample of a human antibody or functional antibody fragment is one thatis encoded by a nucleic acid isolated from a library of antibodysequences of human origin (i.e., such library being based on antibodiestaken from a human natural source). Examples of human antibodies includen-CoDeR-based antibodies as described by [Kontermann R. and & Duebel S.,editors (2001) Antibody Engineering (Springer Laboratory Manual),Springer Verlag; Pluckthun in The Pharmacology of Monoclonal Antibodies,vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp.269-315 (1994); Carlsson R, Soderlind E. (2001) n-CoDeR concept: uniquetypes of antibodies for diagnostic use and therapy. Expert Rev MolDiagn. 1:102-108].

A “humanized antibody” or functional humanized antibody fragment isdefined herein as one that is (I) derived from a non-human source (e.g.,a transgenic mouse which bears a heterologous immune system), whichantibody is based on a human germline sequence; or (II) CDR-grafted,wherein the CDRs of the variable domain are from a non-human origin,while one or more frameworks of the variable domain are of human originand the constant domain (if any) is of human origin.

The phrase “chimeric antibody,” as used herein, refers to an antibodycontaining sequence derived from two different antibodies whichtypically originate from different species. Most typically, chimericantibodies comprise human and murine antibody fragments, generally humanconstant and mouse variable regions.

An antibody of the invention may be derived from a recombinant antibodygene library. The development of ttechnologies for making repertoires ofrecombinant human antibody genes, and the display of the encodedantibody fragments on the surface of filamentous bacteriophage, hasprovided a recombinant means for directly making and selecting humanantibodies, which also can be applied to humanized, chimeric, murine ormutein antibodies. The antibodies produced by phage technology areproduced as antigen binding fragments—usually Fv or Fab fragments—inbacteria and thus lack effector functions. Effector functions can beintroduced by one of two strategies: The fragments can be engineeredeither into complete antibodies for expression in mammalian cells, orinto bispecific antibody fragments with a second binding site capable oftriggering an effector function. Typically, the Fd fragment (VH-CH1) andlight chain (VL-CL) of antibodies are separately cloned by PCR andrecombined randomly in combinatorial phage display libraries, which canthen be selected for binding to a particular antigen. The Fab fragmentsare expressed on the phage surface, i.e., physically linked to the genesthat encode them. Thus, selection of Fab by antigen binding co-selectsfor the Fab encoding sequences, which can be amplified subsequently. Byseveral rounds of antigen binding and re-amplification, a proceduretermed panning, Fab specific for the antigen are enriched and finallyisolated.

A variety of procedures have been described for deriving humanantibodies from phage-display libraries. Such libraries may be built ona single master framework, into which diverse in vivo-formed (i. e.human-derived) CDRs are allowed to recombine as described by [U.S. Pat.Nos. 6,989,250; 4,816,567]. Alternatively, such an antibody library maybe based on amino acid sequences that have been designed in silico andencoded by nucleic acids that are synthetically created. In silicodesign of an antibody sequence is achieved, for example, by analyzing adatabase of human sequences and devising a polypeptide sequenceutilizing the data obtained there from. Methods for designing andobtaining in silico-created sequences are described; for example, see[Carlsson R, Soderlind E. (2001) n-CoDeR concept: unique types ofantibodies for diagnostic use and therapy. Expert Rev Mol Diagn.1:102-108; U.S. Pat. No. 6,989,250; Knappik A, Ge L, Honegger A, Pack P,Fischer M, Wellnhofer G, Hoess A, Wolle J, Plickthun A, Virnekas B.(2000) Fully synthetic human combinatorial antibody libraries (HuCAL)based on modular consensus frameworks and CDRs randomized withtrinucleotides. J Mol Biol. 296:57-86]. For a review of phage displaytechniques, see [Krebs B, Rauchenberger R, Reiffert S, Rothe C, Tesar M,Thomassen E, Cao M, Dreier T, Fischer D, Höss A, Inge L, KnappikA,Marget M, Pack P, Meng X Q, Schier R, Sohlemann P, Winter J, Wölle J,Kretzschmar T. (2001) High-throughput generation and engineering ofrecombinant human antibodies. J Immunol Methods. 254:67-84].

Alternatively, an antibody of this invention may come from animals. Suchan antibody may be humanized or Human Engineered summarized in [Krebs B,Rauchenberger R, Reiffert S, Rothe C, Tesar M, Thomassen E, Cao M,Dreier T, Fischer D, Höss A, Inge L, Knappik A, Marget M, Pack P, Meng XQ, Schier R, Sohlemann P, Winter J, Wölle J, Kretzschmar T. (2001)High-throughput generation and engineering of recombinant humanantibodies. J Immunol Methods. 254:67-84]; such an antibody may comefrom transgenic animals [see Krebs B, Rauchenberger R, Reiffert S, RotheC, Tesar M, Thomassen E, Cao M, Dreier T, Fischer D, Höss A, Inge L,Knappik A, Marget M, Pack P, Meng X Q, Schier R, Sohlemann P, Winter J,Wölle J, Kretzschmar T. (2001) High-throughput generation andengineering of recombinant human antibodies. J Immunol Methods.254:67-84].

As used herein, different ‘forms’ of antigen, e.g. coagulation factor XIand/or the coagulation factor XIa, are hereby defined as differentprotein molecules resulting from different translational andposttranslational modifications, such as, but not limited to,differences in splicing of the primary FXI transcript, differences inglycosylation, and differences in posttranslational proteolyticcleavage.

As used herein, the term ‘epitope’ includes any protein determinantcapable of specific binding to an immunoglobulin or T-cell receptor.Epitopic determinants usually consist of chemically active surfacegroupings of molecules such as amino acids or sugar side chains andusually have specific three dimensional structural characteristics, aswell as specific charge characteristics. Two antibodies are said to‘bind the same epitope’ if one antibody is shown to compete with thesecond antibody in a competitive binding assay, by any of the methodswell known to those of skill in the art, and if preferably all aminoacids of the epitope are bound by the two antibodies.

The term ‘maturated antibodies’ or ‘maturated antigen-binding fragments’such as maturated Fab variants includes derivatives of an antibody orantibody fragment exhibiting stronger and/or improved binding—i. e.binding with increased affinity—to a given antigen such as FXI.Maturation is the process of identifying a small number of mutationswithin the six CDRs of an antibody or antibody fragment leading to thisaffinity increase. The maturation process is the combination ofmolecular biology methods for introduction of mutations into theantibody and screening for identifying the improved binders.

Pharmaceutical Composition and Administration

The present invention also relates to pharmaceutical compositions whichmay comprise FXI/FXIa antibodies, alone or in combination with at leastone other agent, such as stabilizing compound, which may be administeredin any sterile, biocompatible pharmaceutical carrier, including, but notlimited to, saline, buffered saline, dextrose, and water. Any of thesemolecules can be administered to a patient alone, or in combination withother agents, drugs or hormones, in pharmaceutical compositions where itis mixed with excipient(s) or pharmaceutically acceptable carriers. Inone embodiment of the present invention, the pharmaceutically acceptablecarrier is pharmaceutically inert.

The present invention also relates to the administration ofpharmaceutical compositions. Such administration is accomplishedparenterally. Methods of parenteral delivery include topical,intra-arterial (directly to the tumor), intramuscular, subcutaneous,intramedullary, intrathecal, intraventricular, intravenous,intraperitoneal, intrauterine or intranasal administration. In additionto the active ingredients, these pharmaceutical compositions may containsuitable pharmaceutically acceptable carriers comprising excipients andauxilliaries which facilitate processing of the active compounds intopreparations which can be used pharmaceutically. Further details ontechniques for formulation and administration may be found in the latestedition of Remington's Pharmaceutical Sciences (Ed. Maack Publishing Co,Easton, Pa.).

Pharmaceutical formulations for parenteral administration includeaqueous solutions of active compounds. For injection, the pharmaceuticalcompositions of the invention may be formulated in aqueous solutions,preferably in physiologically compatible buffers such as Hank'ssolution, Ringer's solution, or physiologically buffered saline. Aqueousinjection suspensions may contain substances that increase viscosity ofthe suspension, such as sodium carboxymethyl cellulose, sorbitol, ordextran. Additionally, suspensions of the active compounds may beprepared as appropriate oily injection suspensions. Suitable lipophilicsolvents or vehicles include fatty oils such as sesame oil, or syntheticfatty acid esters, such as ethyl oleate or triglycerides, or liposomes.Optionally, the suspension may also contain suitable stabilizers oragents which increase the solubility of the compounds to allow for thepreparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to theparticular barrier to be permeated are used in the formulation. Suchpenetrants are generally known in the art.

The perenteral administration also comprises methods of parenteraldelivery which also include intra-arterial, intramuscular, subcutaneous,intramedullary, intrathecal, and intraventricular, intravenous,intraperitoneal, intrauterine, vaginal, or intranasal administration.

Kits

The invention further relates to pharmaceutical packs and kitscomprising one or more containers filled with one or more of theingredients of the afore mentioned compositions of the invention.Associated with such container(s) can be a notice in the form prescribedby a governmental agency regulating the manufacture, use or sale ofpharmaceuticals or biological products, reflecting approval by theagency of the manufacture, use or sale of the product for humanadministration.

In another embodiment, the kits may contain DNA sequences encoding theantibodies of the invention. Preferably the DNA sequences encoding theseantibodies are provided in a plasmid suitable for transfection into andexpression by a host cell. The plasmid may contain a promoter (often aninducible promoter) to regulate expression of the DNA in the host cell.The plasmid may also contain appropriate restriction sites to facilitatethe insertion of other DNA sequences into the plasmid to produce variousantibodies. The plasmids may also contain numerous other elements tofacilitate cloning and expression of the encoded proteins. Such elementsare well known to those of skill in the art and include, for example,selectable markers, initiation codons, termination codons, and the like.

Manufacture and Storage

The pharmaceutical compositions of the present invention may bemanufactured in a manner that is known in the art, e.g., by means ofconventional mixing, dissolving, granulating, dragee-making, levigating,emulsifying, encapsulating, entrapping or lyophilizing processes.

The pharmaceutical composition may be provided as a lyophilized powderin 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH rangeof 4.5 to 5.5 that is combined with buffer prior to use.

After pharmaceutical compositions comprising a compound of the inventionformulated in an acceptable carrier have been prepared, they can beplaced in an appropriate container and labeled for treatment of anindicated condition. For administration of anti-coagulation factor XIand/or anti-coagulation factor XIa antibodies, such labeling wouldinclude amount, frequency and method of administration.

IC50/EC50

According to the FDA, IC50 represents the concentration of a compoundthat is required for 50% inhibition of a given biological process. Theantibodies of the present invention exhibit IC50 values 100 μM,preferably 1 μM, more preferred 0.1 μM, more preferred 0.01 μM, morepreferred 0.001 μM, more preferred 0.0001 μM.

Therapeutically Effective Dose

Pharmaceutical compositions suitable for use in the present inventioninclude compositions wherein the active ingredients are contained in aneffective amount to achieve the intended purpose, i.e. treatment of aparticular disease state characterized by the coagulation factor XIand/or the coagulation factor XIa. The determination of an effectivedose is well within the capability of those skilled in the art.

A therapeutically effective dose refers to that amount of protein or itsantibodies, antagonists, or inhibitors that ameliorate the symptoms orcondition. Therapeutic efficacy and toxicity of such compounds can bedetermined by standard pharmaceutical procedures in cell cultures orexperimental animals, e.g., ED₅₀ (the dose therapeutically effective in50% of the population) and LD₅₀ (the dose lethal to 50% of thepopulation). The dose ratio between therapeutic and toxic effects is thetherapeutic index, and it can be expressed as the ratio, ED₅₀/LD₅₀.Pharmaceutical compositions that exhibit large therapeutic indices arepreferred. The data obtained from cell culture assays and animal studiesare used in formulating a range of dosage for human use. The dosage ofsuch compounds lies preferably within a range of circulatingconcentrations what include the ED₅₀ with little or no toxicity. Thedosage varies within this range depending upon the dosage form employed,sensitivity of the patient, and the route of administration.

The exact dosage is chosen by the individual physician in view of thepatient to be treated. Dosage and administration are adjusted to providesufficient levels of the active moiety or to maintain the desiredeffect. Additional factors that may be taken into account include theseverity of the disease state, age, weight and gender of the patient;diet, time and frequency of administration, drug combination(s),reaction sensitivities, and tolerance/response to therapy. Long actingpharmaceutical compositions might be administered every 3 to 4 days,every week, or once every two weeks, or once within a month depending onhalf-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to atotal dose of about 2 g, depending upon the route of administration.Guidance as to particular dosages and methods of delivery is provided inthe literature [see U.S. Pat. No. 6,300,064]. Those skilled in the artwill employ different formulations for polynucleotides than for proteinsor their inhibitors. Similarly, delivery of polynucleotides orpolypeptides will be specific to particular cells, conditions,locations, etc. Preferred specific activities for a radiolabeledantibody may range from 0.1 to 10 mCi/mg of protein [WO008/022295, U.S.Pat. Nos. 4,657,760; 5,206,344; 5,225,212; Riva P, Franceschi G,Frattarelli M, Lazzari S, Riva N, Giuliani G, Casi M, Sarti G, GuiducciG, Giorgetti G, Gentile R, Santimaria M, Jermann E, Maeke H R. (1999)Loco-regional radioimmunotherapy of high-grade malignant gliomas usingspecific monoclonal antibodies labeled with 90Y: a phase I study. ClinCancer Res. 5(10 Suppl):3275s-3280s].

The present invention is further described by the following examples.The examples are provided solely to illustrate the invention byreference to specific embodiments. These exemplifications, whileillustrating certain specific aspects of the invention, do not portraythe limitations or circumscribe the scope of the disclosed invention.

All examples were carried out using standard techniques, which are wellknown and routine to those of skill in the art, except where otherwisedescribed in detail. Routine molecular biology techniques of thefollowing examples can be carried out as described in standardlaboratory manuals, such as [Sambrook, J., Fritsch, E. F. and Maniatis,T. (1989) Molecular Cloning: A laboratory manual, Cold Spring HarborLaboratory Press, Cold Spring Harbor, USA].

Measurement of the Coagulation Factor XI and/or the Coagulation FactorXIa Inhibition in Buffer.

To determine the factor Xa inhibition of the substance listed above, abiological test system is constructed in which the conversion of afactor XIa substrate is used for determining the enzymatic activity ofhuman factor XIa. The determinations are carried out in microtitreplates.

Determination of the Anticoagulatory Activity

The anticoagulatory activity of the test substances is determined invitro in human plasma and/or rabbit plasma and/or rat plasma. To thisend, blood is drawn off in a mixing ratio of sodium citrate/blood of 1/9using a 0.11 molar sodium citrate solution as receiver. Immediatelyafter the blood has been drawn off, it is mixed thoroughly andcentrifuged at about 4000 g for 15 minutes. The supernatant is pipettedoff.

The prothrombin time (PT, synonyms: thromboplastin time, quick test) isdetermined in the presence of varying concentrations of test substanceor the corresponding solvent using a commercial test kit (Neoplastin®from Roche (former Boehringer Mannheim) or Hemoliance® RecombiPlastinfrom Instrumentation Laboratory). The test compounds are incubated withthe plasma at 37° C. for 3 minutes. Coagulation is then started byaddition of thromboplastin, and the time when coagulation occurs isdetermined. The concentration of test substance which effected adoubling of the prothrombin time is determined.

The thrombin time (TT) is determined in the presence of varyingconcentrations of test substance or the corresponding solvent using acommercial test kit (thrombin reagent from Roche). The test compoundsare incubated with the plasma at 37° C. for 3 minutes. Coagulation isthen started by addition of the thrombin reagent, and the time whencoagulation occurs is determined. The concentration of test substancewhich effects a doubling of the thrombin time is determined.

The activated partial thromboplastin time (aPTT) is determined in thepresence of varying concentrations of test substance or thecorresponding solvent using a commercial test kit (PTT reagent fromRoche). The test compounds are incubated with the plasma and the PTTreagent (cephalin, kaolin) at 37° C. for 3 minutes. Coagulation is thenstarted by addition of 25 mM calcium chloride, and the time whencoagulation occurs is determined. The concentration of test substancewhich effects a doubling of the aPTT is determined.

Concentrations of the antibodies of the present invention lead to adoubling of the aPTT at a concentration of 100 μM, preferably at aconcentration of 1 μM, more preferred at a concentration of 0.1 μM, morepreferred at a concentration of 0.01 μM, more preferred at aconcentration of 0.001 μM, more preferred at a concentration of 0.0001μM, more preferred at a concentration of 0.00001 μM.

Therapeutic Use

Anti-coagulation factor XI antibodies and/or anti-coagulation factor XIaantibodies of the invention may be administrated to any subject in whichinhibition of the coagulation cascade and inhibition of plateletaggregation and inhibition of thrombosis would be beneficial.

Therefore, the anti-coagulation factor XI antibodies and/oranti-coagulation factor XIa antibodies of the invention are suitable forthe treatment and/or prophylaxis of coagulation-related disease inhumans as well as in animals.

The term “thromboembolic diseases” includes diseases like myocardialinfarction (MI) or acute myocardial infarction (AMI) with and without STelevation on ECG (STEMI and non-STEMI), stable Angina Pectoris as wellas unstable Angina Pectoris, re-occlusion and re-stenosis followingcoronary intervention like angioplasty or coronary artery bypass graft(CABG), peripheral artery occlusive disease (PAOD), pulmonary embolism(PE), deep vein thrombosis (DVT) as well as renal vein thrombosis,transient ischemic attack (TIA), thrombotic stroke and thromboembolicstroke.

These antibodies are also useful for the treatment and prevention ofcardiogenic thromboembolism like cerebral ischemia, apoplectic stroke aswell as systemic thromboembolism, for the treatment of patients withirregular heartbeat or abnormal heart rhythm e.g. for patients withatrial fibrillation, for patients with valvular heart disease of withartificial heart valves. Further on, these antibodies could be helpfulin the treatment of patients with disseminated intravascular coagulation(DIC).

Thromboembolic complications may be caused by atherosclerotic lesions ofthe vessel wall, especially disturbance of endothelial function, whichmay lead to acute thrombotic occlusions. Atherosclerosis is amultifactorial disorder which depends on a large number ofcardiovascular risk factors. Clinical studies have shown thatprophylaxis with anticoagulants does not definitively influence thecourse of the arterial vascular disorder. Targeted treatment of the riskfactors in conjunction with an antithrombotic therapy is thereforeadvantageous. Risk factors for coronary, peripheral and cerebralvascular disorders are, for example: elevated serum cholesterol levels,arterial hypertension, cigarette smoking, and diabetes mellitus. Theprinciples of preventive medicine are based on elimination of these riskfactors. Besides a change in lifestyle, also included arepharmacological measures such as, for example, antihypertensive therapy,lipid-lowering medicaments or thrombosis prophylaxis. In addition,combination with coronary therapeutic agents is suitable for thetreatment where there is preexistent coronary heart disease.

Thromboembolic complications are involved in microangiopathic hemolyticanemia (MAHA), extracorporeal blood circulation like haemodialysis andaortic valve replacement.

In addition the antibodies of this invention are useful for thetreatment or for prophylaxis of inflammatory diseases like rheumatoidarthritis (RA), or like neurological diseases like Alzheimer's disease(AD). Further on, these antibodies could be useful for the treatment ofcancer and metastasis, thrombotic microangiopathy (TMA), age relatedmacular degeneration, diabetic retinopathies, diabetic nephropathies, aswell as other microvascular diseases.

The antibodies of this invention are also useful for the treatment ofthromboembolic complications following the surgery of tumor patients ortumor patients undergo a chemo- and/or radiotherapy.

The antibodies of this invention are also useful for the treatmentand/or prophylaxis of Dialysis patients, especially the Cimino-fistulaprevention of shunt thrombosis in hemodialysis. Hemodialysis can beperformed using native arteriovenous fistulae, synthetic loop grafts,large-bore central venous catheters or other devices consisting ofartificial surfaces. Administration of antibodies of this invention willprevent the formation of clot within the fistula (and propagation ofembolized clot in the pulmonary arteries), both during dialysis andshortly thereafter.

The antibodies of this invention are also useful for the treatmentand/or prophylaxis of patients undergoing intracardiac andintrapulmonary thromboses after cardiopulmonary bypass surgeries (e.g.,ECMO: Extra-corporeal membrane oxygenation).

Beneath the requirement for systemic anticoagulation, and the mechanicalstability and duration of the device, major limitations of ventricularassist devices are the high incidence of thromboembolic events.Therefore, the antibodies of this invention are also useful for thetreatment and/or prophylaxis of patients getting a left ventricularassist device.

There is a high need for anticoagulation in dialysis patients withoutincreasing the risk of unwanted bleeding events and where the incidenceof venous thromboembolism (VTE) and atrial fibrillation (e.g. end-stagerenal disease in hemodialysis patients) in this population is high. Theantibodies of this invention are also useful for the treatment and/orprophylaxis of these types of patients.

The antibodies of this invention are also useful for the treatmentand/or prophylaxis of patients affected with idiopathic thrombocytopenicpurpura (IPT). These patients have an increased thrombotic risk comparedto the general population. The concentration of the coagulation factorFXI is significantly higher in ITP patients compared to controls andaPTT is significantly longer in ITP patients.

The antibodies of this invention are also useful for the treatmentand/or prophylaxis of pulmonary hypertension.

The term “pulmonary hypertension” follows the guidelines defined by theWorld Health Organization WHO (Clinical Classification of PulmonaryHypertension, Venice 2003), e.g. the pulmonary arterial hypertension,pulmonary hypertension caused by left ventricular disease, pulmonaryhypertension caused by lung diseases and/or hypoxia, by blood clots,artery constriction, and other diseases like chronic thromboembolicpulmonary hypertension (CTEPH).

The term “pulmonary hypertension” also includes diseases like idiopathicpulmonary arterial hypertension IPAH, the familial pulmonary arterialhypertension (FPAH), the associated pulmonary arterial hypertension(APAH), which could be associated with collagenosis, congenital systemicpulmonary shunt vitia, HIV infections, or the administration of certaindrugs in combination with diseases like thyroid diseases, Glycogenstorage disease (GSD), Morbus Gaucher, hereditary hemorrhagicteleangiectasy, hemoglobinopathy, and/or myeloproliferative disorders.

The antibodies of this invention are useful for the treatment and/or theprophylaxis of diseases like pulmonary veno-occlusive disease, theplmonary capillary hemangiomatosis (PCH), as well as the persistentpulmonary hypertension of the newborn.

The term “pulmonary hypertension” also includes diseases like thechronic obstructive pulmonary disease (CODP), interstitial lung disease(ILD), sleep apnea, alveolar hyperventilation, altitude sickness, aswell as constitutional dysplasia.

Diseases caused by chronic thromboembolic pulmonary hypertension (CTEPH)can be associated with proximal and/or distal pulmonary arteryobstruction, or with non-thrombotic lung emboli like cancer, parasites,or contaminants.

Further on the antibodies of this invention can be used for thetreatment and/or prophylaxis of the pulmonary hypertension caused bysarcoidosis, histiocytosis X, and lymphangiomatosis.

In addition, the antibodies of this invention may be useful for thetreatment and/or prophylaxis of pulmonary and/or hepatic fibrosis.

The antibodies of this invention are also useful for the treatmentand/or prophylaxis of sepsis, the systemic inflammatory syndrome (SIRS),organ dysfunction, multiple organ dysfunction syndrome (MODS) acuterespiratory distress syndrome (ARDS), acute lung injury (ALl),disseminated intravascular coagulation (DIC).

The term “sepsis” defines the occurrence of an infection or of thesystemic inflammatory response syndrome (SIRS). SIRS is mainly inducedby infections, but can also take place following lesion, burn, shock,operations, ischemia, pancreatitis, reanimation or tumor affection. Inthe course of a sepsis, the coagulation cascade can be activated, aprocess termed as disseminated intravascular coagulation or shortly DIC.This can lead to the formation of microthrombi and to secondarycomplications.

In addition, sepsis or SIRS can lead to endothelial dysfunction, leadingto an increase in permeability vessel. In the course of sepsis or SIRS,combined failure of several organs can take place, e.g. kidney failure,liver failure, lung failure, failure of the cardio-vascular system.

Pathogenic organism inducing sepsis or SIRS are gram-positive andgram-negative bacteria, fungi, viruses, and/or eukaryotic pathogens.

DIC and/or SIRS can occur in line with a sepsis, but can also occur dueto an operation, tumor diseases, burning, or other types of injury.

During DIC, an activation of the coagulation cascade takes place at thesurface of damaged vessels or other types of tissues. This could lead tothe formation of microthrombi, which on their part are leading to theocclusion of small vessels.

In one embodiment, the anti-coagulation factor XI antibodies and/or theanti-coagulation factor XIa antibodies is used in combination with otherdrugs for the treatment and/or prophylaxis of the already mentioneddiseases.

In the following, examples for suitable combinations are listed up andtherefore are preferable mentioned:

Combination with lipid lowering compounds, especially inhibitors of the3-hydroxy-3-methyl-glutaryl-CoA reductase like Lovastatin (Mevacor; U.S.Pat. No. 4,231,938), Simvastatin (Zocor; U.S. Pat. No. 4,444,784),Pravastatin (Pravachol; U.S. Pat. No. 4,346,227), Fluvastatin (Lescol;U.S. Pat. No. 5,354,772), and Atorvastatin (Lipitor; U.S. Pat. No.5,273,995).

Combination with compounds suitable for the treatment of coronarydiseases and/or compounds exhibiting vasodilatative activitiesespecially inhibitors of the angiotensin converting enzyme, likeCaptopril, Lisinopril, Enalapril, Ramipril, Cilazapril, Benazepril,Fosinopril, Quinapril, and Perindopril, or antagonists of theangiotensin II receptor like Embusartan (U.S. Pat. No. 5,863,930),Losartan, Valsartan, Irbesartan, Candesartan, Eprosartan, and Temisarta,or antagonists of the 3-adrenergic receptor like Carvedilol, Alprenolol,Bisoprolol, Acebutolol, Atenolol, Betaxolol, Carteolol, Metoprolol,Nadolol, Penbutolol, Pindolol, Propanolol and Timolol, or thecombination with antagonists of the alphal adrenergic receptor likePrazosin, Bunazosin, Doxazosin, and Terazosin.

Combination with diuretics Hydrochlorothiazide, Furosemide, Bumetanide,Piretanide, Torasemide, Amiloride, and Dihydralazine.

Combination with inhibitors of calcium channels like Verapamil andDiltiazem, dihydropyridine derivatives like Nifedipin (Adalat),Nitrendipin (Bayotensin), Isosorbid-5-mononitrat, Isosorbid-dinitrat,and Glyceroltrinitrat.

Combination with compounds which are leading to an increase in theconcentration of cyclic guanosine monophosphate (cGMP) like stimulatorsof the soluble Guanylatcyclase (WO 98/16223, WO 98/16507, WO 98/23619,WO 00/06567, WO 00/06568, WO 00/06569, WO 00/21954, WO 00/66582, WO01/17998, WO 01/19776, WO 01/19355, WO 01/19780, WO 01/19778, WO07/045366, WO 07/045367, WO 07/045369, WO 07/045370, WO 07/045433).

Combination with other inhibitors of the coagulation cascade likePlasminogen activators (thrombolytics/Fibrinolytics) as well ascompounds increasing Thrombolysis and/or Fibrinolysis or inhibitors ofthe plasminogen activator or inhibitors of the Thrombin-aktiviertenFibrinolyse-Inhibitors (TAFI-Inhibitoren) like the tissue plasminogenactivator (t-PA), Streptokinase, Reteplase, and Urokinase.

Combination with anticoagulants like non-fractionated heparins, lowmolecular weight Heparins, Heparinoid, Hirudin, Bivalirudin and/orArgatroban.

Further combination therapies are the co-administration of theanti-coagulation factor XI antibodies and/or the anti-coagulation factorXIa antibodies with an antibiotic therapy, antifungal therapeutics, andantiviral therapeutics.

Additionally, combinations of the anti-coagulation factor XI antibodiesand/or the anti-coagulation factor XIa antibodies

with vasopressors like Norepinephrine, Dopamine, and Vasopressin

inotropic therapies, e.g. Dobutamine

corticosteroids, like hydrocortison or fludrocortisone

recombinantly expressed activated protein C

blood products, like fresh frozen plasma, erythrocyte concentrates,and/or thrombocyte concentrates

Another embodiment of this invention is the usage of theanti-coagulation factor XI antibodies and/or anti-coagulation factor XIaantibodies as an anticoagulant for blood probes, blood preservations,other plasma products or biological samples, which contain thecoagulation factor XI and/or the coagulation factor XIa. These samplesare characterized in such a way, that an effective concentration of theantibodies has been added to avoid in vitro coagulation.

The anti-coagulation factor XI antibodies and/or anti-coagulation factorXIa antibodies of this invention can also be used for inhibition of exvivo coagulation, like the preparation of blood catheters or othermedicinal additives or devices, for the coating of artificial surfacesof in vivo as well as for ex vivo used medicinal additives, devices, orother biological samples, which contain the coagulation factor XI and/orthe coagulation factor XIa.

Example 1: Identification of Antibodies

Tools Used for Phage Selections:

Proteins used for the isolation of human antibodies of the presentinvention were obtained from different sources as listed in Tab. 1.Proteins were biotinylated using an appr. 2-fold molar excess ofbiotin-LC-NHS (Pierce; Cat. NO: 21347) according to manufacturer'sinstructions and desalted using Zeba desalting columns (Pierce; Cat. NO:89889).

TABLE 1 List of proteins used in phage selections and screening: ProteinOrigin Supplier (Cat. NO:) hFX human Haematologic Technologies Inc.(HCX-0050) hFXa human Haematologic Technologies Inc. (HCXA-0060) rbFXrabbit In house rbFXa rabbit In house hPrekallikrein human EnzymeResearch Laboratories HPK 2640 AL hKallikrein human Enzyme ResearchLaboratories HPKA 1303 Aprotinin bovine Sigma (A1153)

Phage Selections:

The isolation of human antibodies of the present invention or antigenbinding fragments thereof was performed by phage display technologyemploying DYAX's human Fab antibody library FAB-310 (DYAX Corp.,Cambridge, Mass.; described in Hoet et al., Nat. Biotech. 2005,23:344-8), which is a Fab library combining natural and syntheticdiversity. Tab. 2 to 6 summarizes different strategies that wereemployed to select antibodies covering multiple epitopes.

TABLE 2 Selection strategy I: Prior to each round of selection adepletion step on biotinylated Kallikrein/pre-Kallilrein (500 nM) wasincluded. Round of selection: Strategy IA Strategy IB 1 500 nMbiotinylated hFXI 2 200 nM biotinylated hFXI 200 nM biotinylated rbFXI 3100 nM biotinylated hFXI 200 nM biotinylated hFXI 4 100 nM biotinylatedrbFXI

TABLE 3 Selection strategy II: As described for Strategy I, prior toeach eound of selection a depletion step on biotinylatedKallikrein/pre-Kallikrein (500 nM) was included. In addition selectionswere performed in the presence of the complex hFXIa (500 nM)/aprotinin(25 μM). Round of selection: Strategy IIA Strategy IIB 1 500 nMbiotinylated hFXI 2 200 nM biotinylated hFXI 200 nM biotinylated rbFXI 3100 nM biotinylated hFXI 200 nM biotinylated hFXI 4 100 nM biotinylatedrbFXI

TABLE 4 Selection strategy III: Prior to each round of selection adepletion step on biotinylated Kallikrein/pre-Kallikrein (500 nM) wasincluded. Round of selection: Strategy IIIA Strategy IIIB 1 500 nMbiotinylated hFXIa 2 200 nM biotinylated hFXIa 200 nM biotinylatedrbFXIa 3 100 nM biotinylated hFXIa 200 nM biotinylated hFXIa 4 100 nMbiotinylated rbFXIa

TABLE 5 Selection strategy IV: As described for Strategy III, prior toeach round of selection a depletion step on biotinylatedKallikrein/pre-Kallikrein (500 nM) was included. In addition selectionswere performed in the presence of the complex hFXIa (500 nM)/ aprotinin(25 μM). Round of selection: Strategy IVA Strategy IVB 1 500 nMbiotinylated hFXIa 2 200 nM biotinylated hFXIa 200 nM biotinylatedrbFXIa 3 100 nM biotinylated hFXIa 200 nM biotinylated hFXIa 4 100 nMbiotinylated rbFXIa

TABLE 6 Selection strategy V: Prior to each round of selection depletionsteps on biotinylated Kallikrein/pre-Kallikrein (500 nM) andbiotinylated hFXI (500 nM) were included. Round of selection: Strategy V1 500 nM biotinylated hFXIa 2 200 nM biotinylated rbFXIa 3 200 nMbiotinylated hFXIa 4 100 nM biotinylated rbFXIa

Standard buffers used in this example are:

1×PBS: from Sigma (D5652-501)

PBST: 1×PBS supplemented with 0.05% Tween20 (Sigma, P7949)

Blocking buffer: PBST supplemented with 3% BSA (Sigma A4503)

Precipitation buffer: 20% PEG6000 (Calbiochem, 528877) in 2.5 M NaCl

Cell panning-buffer: PBS supplemented with 3% FBS (GIBCO, 10082) and0.01% NaN₃ (Sigma, 71289)

The general method used for the library selection has been described byHoet et. al. (Hoet R M, Cohen E H, Kent R B, Rookey K, Schoonbroodt S,Hogan S, Rem L, Frans N, Daukandt M, Pieters H, van Hegelsom R, Neer NC, Nastri H G, Rondon I J, Leeds J A, Hufton S E, Huang L, Kashin I,Devlin M, Kuang G, Steukers M, Viswanathan M, Nixon A E, Sexton D J,Hoogenboom H R, Ladner R C. (2005) Generation of high-affinity humanantibodies by combining donor-derived and syntheticcomplementarity-determining-region diversity. Nat Biotechnol.23:344-348). Briefly, the Fab antibody library is precipitated by adding1/5 volume of precipitation buffer followed by an incubation on ice for1 h and a centrifugation step (1 h at 5500 rpm). The precipitatedlibrary was subsequently resuspended in 1 ml blocking buffer andincubated at r.t. for 30 min.

Meanwhile, aliquots of streptavidin-coated Dynabeads M280 (Invitrogen,11206D) were prepared by washing 3 times with PBST. After that somealiquotes were mixed with biotinylated Kallikrein/pre-Kallikrein (500nM) or biotinylated hFXI (500 nM) while the remaining were mixed withthe biotinylated target protein as indicated in Tab. 2 to 6 The mixtureswere incubated ON at 4° C. on an end-to-end rotator and subsequentlywashed 5 times in 1 ml PBST. Coated beads were finally blocked byresuspension in 1 ml blocking buffer, aliquoted in 5 tubes follwed bycollection of the beads and removal of the supernatant.

5 sequential depletion steps were done as indicated by adding theblocked library (described above) to blocked Dynabeads coated withbiotinylated Kallikrein/pre-Kallikrein (500 nM) or biotinylated hFXI(500 nM) and incubated at r.t. for 10 min while rotating. Aftercollection of the beads on a magnetic rack, the supernatant was clearedby centrifugation and mixed with blocked Dynabeads coated with targetprotein. After 30 min incubation on an end-to-end rotator the sampleswere washed 3 times with blocking buffer followed by 9 times washingwith PBST. Half of the resuspended beads containing enriched phages werethen used to infect exponentially growing E. coli TG1 (from Stratagene)for preparation of new phage stocks used in the next selection roundaccording to the strategies depicted in Tab. 2-6 In more detail, 6 ml ofTG1-culture were infected with 500 μl of dynabead/phage suspension for30 min at 37° C. without shaking. After that aliquots were taken foroutput tirtration. The remaining culture was centrifuged for 15 min at5000 rpm and the resulting pellet was resuspended in 2 ml 2×YT andplated on agar plates (2×YT, 100 μg/ml ampicillin, 2% glucose). Afterover night incubation at 37° C., cells were scraped off in 5 ml 2×YT andused to inoculate a fresh culture of 20 ml 2×YT (100 μg/ml Amp) at anOD600 of 0.05 and for the preparation of glycerol stocks. The freshliquid culture was shaked for about 2 h at 37° C. until OD600 0.5 to 0.8was reached, then 5 ml culture were mixed with M13 helperphage M123K07(Invitogen 420311) at an multiplicity of infection (MOI) of about 20.After slow shaking for 30 min at 37° C. 30 ml prewarmed 2×YT (100 μg/mlampicillin, 20 μg/ml kanamycin, f.c.) was added and the culture skakedON at 30° C. Next morning the supernatant was harvested bycentrifugation at 6000 rpm and cleared by filtration through Steriflip(0.22 μm; Milipore SCGP00525). Subsequently, phages were precipitated asdescriped above and resuspended in 1 ml blocking buffer (or cell panningbuffer) for use in the next selection round. Aliquots were used for thedetermination of the input titer.

Enzyme-Linked Immunosorbent Assay (ELISA):

Phage ELISA:

Phage pools after different rounds of selection were analyzed for theenrichment of specific binder by ELISA on biotinylated target proteins.Briefly, aliquots from the glycerol stocks were plated on 2×YT (100mg/ml ampicillin, 1% glucose) ON at 37° C. Single colonies were pickedinto wells of MTP containing 100 μl medium (2×YT, 100 μg/ml ampicillin,1% glucose) and shaked overnight at 37° C. Phage expression wasperformed by adding 10 μl of overnight culture to 190 μl fresh medium(2×YT supplemented with 100 μg/ml ampicillin) containing helperphageM123K07 (Invitogen 420311) and incubating at 200 rpm and 37° C. in96-well MTP until an OD600 of ˜0.5 was reached.

96-well ELISA-plates pre-coated with streptavidin (Pierce, 15500) werecoated over night at 4° C. with 1 μg/ml biotinylated target protein. Thenext day plates were washed 7 times with PBST, treated with blockingreagent, and washed again 3 times with PBST. Meanwhile, ON phagecultures were mixed with 100 μl blocking buffer. After that 100 μl ofthe blocked phages were transferred per well and incubated for 1 h atr.t. After washing 7 times with PBST, anti M13 antibody coupled to HRP(GE Healthcare, 27-9421-01; 1:2500 diluted in PBST) was added, incubatedfor 1 h at r.t. and wells were washed again 7 times. Color reaction wasdeveloped by addition of 100 μl TMB (Invitrogen, 2023) and stopped after5-15 min by adding 100 μl H₂SO₄ (Merck, 1120801000). Colorimetricreaction was recorded at 450 nM in a plate reader (Tecan).

TABLE 7 Hit rates of pools from different strategies in Fab/Phage ELISA:numbers refer to % hit rate on human/rabbit/both targets(crossreactive), respectively; n.a.: not applicable. IA IB IIA IIB IIIAIIIB IVA IVB V 2^(nd) 3/1/0 1/0/0 6/5/4 0/1/0 1/1/0 1/0/0 0/0/0 0/0/00/0/0 round 3^(rd) 77/20/18 22/18/16 80/30/31 41/28/32 35/8/3 11/18/935/3/0 10/13/10 13/23/9 round 4^(th) n.a. 74/72/63 n.a. 80/84/67 n.a.42/72/34 n.a. 86/90/73 65/70/53 round

Recloning of sFabs by GenIII-Removal for sFab Screening

For the generation of soluble Fab fragements (sFabs) phagemid DNA fromselection rounds 2, 3 and 4 was isolated and digested with restrictionenzymes Mlul (New England Biloabs, R0198L) according to the providersinstructions. In order to remove the gene III containing fragment thevector was gele-extracted and submitted to a kill-cut with Ndel (NewEngland Biolabs, R0111S). After EtOH-precipiation the resulting fragmentwas re-ligated and constructs were transformed into chemically competentE. coli Top10 using standard methods.

Example 2: Anti-Coagulation Factor XI Antibodies and/or Anti-CoagulationFactor XIa Antibodies

The antibodies, antigen-binding antibody fragments, and variants of theantibodies and fragments of the invention are comprised of a light chainvariable region and a heavy chain variable region. Variants of theantibodies or antigen-binding fragments contemplated in the inventionare molecules in which the binding activity of the antibody orantigen-binding antibody fragment for the coagulation factor XI and/orthe coagulation factor XIa are maintained

The present invention provides antibodies or antigen-binding fragments

whereby the amino acid sequences of the variable heavy and light regionsare at least 60%, more preferred 70%, more preferred 80%, or 90%, oreven more preferred 95% identical to SEQ ID NO: 1 for the DNA sequenceand SEQ ID NO: 19 for the amino acid sequence for the variable lightchain domain and, identical to SEQ ID NO: 2 for the DNA sequence and 20for the amino acid sequence for the variable heavy chain domain, or

whereby for the maturated forms of these antibodies the amino acidsequences of the variable heavy chain and light chain domain are atleast 60%, more preferred 70%, more preferred 80%, or 90%, or even morepreferred 95% identical thereto.

whereby the amino acid sequences of the CDRs are at least 60%, morepreferred 70%, more preferred 80%, more preferred 90%, or even morepreferred 95% identical to SEQ ID NO: 3, 4 and 5 for the DNA sequenceand SEQ ID NO: 21, 22 and 23 for the amino acid sequence for the heavychain domain, and to SEQ ID NO: 6, 7, and 8 for the DNA sequence SEQ IDNO: 24, 25, and 26 for the amino acid sequence for the variable lightchain domain.

The present invention further provides antibodies or antigen-bindingfragments

whereby the amino acid sequences of the variable heavy and light regionsare at least 60%, more preferred 70%, more preferred 80%, or 90%, oreven more preferred 95% identical to SEQ ID NO: 9 for the DNA sequenceand SEQ ID NO: 27 for the amino acid sequence for the variable lightchain and, identical to SEQ ID NO: 2 for the DNA sequence and 20 for theamino acid sequence for the variable heavy chain domain, or

whereby for the maturated forms of these antibodies the amino acidsequences of the variable heavy chain and light chain domain are atleast 60%, more preferred 70%, more preferred 80%, or 90%, or even morepreferred 95% identical thereto.

whereby the amino acid sequences of the CDRs are at least 60%, morepreferred 70%, more preferred 80%, more preferred 90%, or even morepreferred 95% identical to SEQ ID NO: 10 for the DNA sequence and SEQ IDNO: 28 for the amino acid sequence for the variable light chain domain.

The present invention also provides antibodies or antigen-bindingfragments

whereby the amino acid sequences of the variable heavy and light regionsare at least 60%, more preferred 70%, more preferred 80%, or 90%, oreven more preferred 95% identical to SEQ ID NO: 11 for the DNA sequenceand SEQ ID NO: 29 for the amino acid sequence for the variable lightchain domain and, identical to SEQ ID NO: 12 for the DNA sequence and 30for the amino acid sequence for the variable heavy chain domain, or

whereby for the maturated forms of these antibodies the amino acidsequences of the variable heavy chain and light chain domain are atleast 60%, more preferred 70%, more preferred 80%, or 90%, or even morepreferred 95% identical thereto.

whereby the amino acid sequences of the CDRs are at least 60%, morepreferred 70%, more preferred 80%, more preferred 90%, or even morepreferred 95% identical to SEQ ID NO: 13, 14 and 15 for the DNA sequenceand SEQ ID NO: 31, 32, and 33 for the amino acid sequence for the heavychain domain, and to SEQ ID NO: 16, 17, and 18 for the DNA sequence SEQID NO: 34, 35, and 36 for the amino acid sequence for the variable lightchain domain.

Example 3: Determination of the Anticoagulatory Activity Using theActivated Partial Thromboplastin Time (aPTT) Assay

The anticoagulatory activity of the antibodies 076D-M007-H04,076D-M007-H04-CDRL3-N110D, and 076D-M028-H17 were tested by using theactivated partial thromboplastin time (aPTT) assay.

Values for the concentrations needed for doubling the aPTT in human andin rabbit plasma are given in table 8:

TABLE 8 antibody concentrations needed for doubling the aPTT of humanand rabbit plasma. 2xaPTT human [μM] 2xaPTT rabbit [μM] 076D-M028-H170,3 0,003 M076D-M007-H04 0,9 0,178 076D-M007-H04-CDRL3-N110D 0,3 0,063

TABLE 9 show examples and sequences of antibodies of thepresent invention. Des- SEQ crip- ID tion NO type Sequence H04-   1 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC VlGCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAGGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA H04-  2 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCH04   3 DNA GGCTTTACCTTTAGCCAGTATGGCATGGAT CDR H1 H04   4 DNAGGCATTGGCCCGAGCGGCGGCAGCACCGTG CDR H2 H04   5 DNAACCCGCGGCGGCCCGTATTATTATTATGGCATGGATG CDR TG H3 H04   6 DNACAGGCGAGCCAGGATATTAGCAACTATCTGAAC CDR L1 H04   7 DNAGATGCGAGCAACCTGGAAACC CDR L2 H04   8 DNA CAGCAGGCGAACAGCTTTCCG CDR L3N11   9 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0D-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA N11 10 DNA CAGCAGGCGGATAGCTTTCCG 0D- Vh H17-  11 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC VlGCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGCGCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTATCAGCAGCGCCCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCACCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAAACTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTGC GTTTGGCCAGGGCACCCGCCTGGAAATTAAAH17-  12 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC H17 13 DNA GGCTTTACCTTTAGCGATTATGAAATGGCG CDR H1 H17  14 DNAAGCATTGTGCCGAGCGGCGGCTGGACCCTG CDR H2 H17  15 DNAGCGACCTGGGGCGATAGCTGGGGCTTTGATTTT CDR H3 H17  16 DNACGCGCGAGCCAGGGCATTAGCAGCTGGCTGGCG CDR L1 H17  17 DNAGATGCGAGCACCCTGCAGAGC CDR L2 H17  18 DNACAGCAGGCGGATAGCTTTCCGATTGCGTTTGGC CDR L3 H04-  19 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ VlQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT aaISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK H04-  20 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV VhRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN aaSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWG QGTTVTVSS H04  21 PRT GFTFSQYGMDCDR H1 aa H04  22 PRT GIGPSGGSTV CDR H2 aa H04  23 PRT TRGGPYYYYGMDV CDRH3 aa H04  24 PRT QASQDISNYLN CDR L1 aa H04  25 PRT DASNLET CDR L2 aaH04  26 PRT QQANSFP CDR L3 aa N11  27 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0D-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK aa N11  28 PRT QQADSFP 0D- Vh aa H17- 29 PRT DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ VlQRPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLT aaINSLQPENFATYYCQQADSFPIAFGQGTRLEIK H17-  30 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV VhRQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN aaSKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG TLVTVSS H17  31 PRT GFTFSDYEMA CDRH1 aa H17  32 PRT SIVPSGGWTL CDR H2 aa H17  33 PRT ATWGDSWGFDF CDR H3 aaH17  34 PRT RASQGISSWLA CDR L1 aa H17  35 PRT DASTLQS CDR L2 aa H17  36PRT QQADSFPIAFG CDR L3 aa M00  37 DNAGAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 9-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC G02-GAGCGGCTTTACCTTTAGCCGCTATATTATGCATTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCCTGACCAGCTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAATTTGAAAACGCGTATCATTATTATTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGACC GTGAGCAGC M00  38 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 9-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC G02-GCGAGCGGCGATATTGGCAACGCGCTGGGCTGGTAT VlCAGCAGAAACCGGGCAAAGCGCCGCGCCTGCTGATTAGCGATGCGAGCACCCTGCAGAGCGGCGTGCCGCTGCGCTTTAGCGGCAGCGGCAGCGGCACCGAATTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCTGCAGGGCTATAACTATCCGCGCAC CTTTGGCCAGGGCACCAAACTGGAAATTCGCG16-  39 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCTGGTATCCGATGCAGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTAGCAGCAGCGGCGGCGGCACCTATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGATTGGGGCTATAGCAACTATGTGATGGATCTGGGCCTGGATTATTGGGGCCAGGGCACCCTGGTGAC CGTGAGCAGC G16-  40 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC VlCTGAGCGCGGGCGAACGCGCGACCCTGAGCTGCCG CGCGAGCCAGACCGTGAGCAGCAGCCTGGCGTGGTATCAGCATAAACCGGGCCAGGCGCCGCGCCTGCTGATTTATGAAACCAGCAACCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGGAACCGGAAGATTTTGCGGTGTATTATTGCCAGCATCGCAGCAACTGGCCGCCGA CCTTTGGCCCGGGCACCAAAGTGGATATTAAAG11-  41 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCACCTATAGCATGGGCTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCGATACCGATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAACGCACCATGGTGCGCGATCCGCGCTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGA CCGTGAGCAGC G11-  42 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC VlCTGAGCCCGGGCGAACGCGCGACCCTGAGCTGCCG CGCGAGCCAGAGCGTGAGCAGCTATCTGGCGTGGTATCAGCAGCGCCTGGGCCAGAGCCCGCGCCTGCTGATTTATGATGCGAGCAGCCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCAACCTGGTGA CCTTTGGCCAGGGCACCCGCCTGGAAATTAAAM01  43 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 4-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC G02-GAGCGGCTTTACCTTTAGCCTGTATTATATGAAATGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCAGCATTAGCCCGAGCGGCGGCTTTACCAGCTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAATTTGAAAACGCGTATCATTATTATTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGACCGT GAGCAGC M01  44 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC 4-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC G02-GCGAGCCAGGATATTAACATTTGGCTGGCGTGGTATC VlAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTA GCGCGGCGAGCACCGTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACACCCTGCAGCCGGATGATTTTGCGACCTATTATTGCCAGCAGGCGGCGAGCTTTCCGCTGAC CTTTGGCGGCGGCACCAAAGTGGAAATGAAAM01  45 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 3-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC J04-GAGCGGCTTTACCTTTAGCACCTATAGCATGGGCTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCGATACCGATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAACGCACCATGGTGCGCGATCCGCGCTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGA CCGTGAGCAGC M01  46 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC 3-CTGAGCCCGGGCGAACGCGCGACCCTGAGCTGCCG J04-CGCGAGCCAGAGCGTGAGCAGCTATCTGGCGTGGTA VlTCAGCAGCGCCTGGGCCAGAGCCCGCGCCTGCTGATTTATGATGCGAGCAGCCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGAAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCAACCTGGTGA CCTTTGGCCAGGGCACCCGCCTGGAAATTAAAA10-  47 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCTGGTATCCGATGCAGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTAGCAGCAGCGGCGGCGGCACCTATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGATTGGGGCTATAGCAACTATGTGATGGATCTGGGCCTGGATTATTGGGGCCAGGGCACCCTGGTGAC CGTGAGCAGC A10-  48 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC VlCTGAGCGCGGGCGAACGCGCGACCCTGAGCTGCCG CGCGAGCCAGACCGTGAGCAGCAGCCTGGCGTGGTATCAGCATAAACCGGGCCAGGCGCCGCGCCTGCTGATTTATGAAACCAGCAACCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGGAACCGGAAGATTTTGCGGTGTATTATTGCCAGCATCGCAGCAACTGGCCGCCGA CCTTTGGCCCGGGCACCAAAGTGGATATTAAAM10-  49 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCTGGTATCCGATGCAGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTAGCAGCAGCGGCGGCGGCACCTATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGATTGGGGCTATAGCAACTATGTGATGGATCTGGGCCTGGATTATTGGGGCCAGGGCACCCTGGTGAC CGTGAGCAGC M10-  50 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC VlCTGAGCGCGGGCGAACGCGCGACCCTGAGCTGCCG CGCGAGCCAGACCGTGAGCAGCAGCCTGGCGTGGTATCAGCATAAACCGGGCCAGGCGCCGCGCCTGCTGATTTATGAAACCAGCAACCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGGAACCGGAAGATTTTGCGGTGTATTATTGCCAGCATCGCAGCAACTGGCCGCCGA CCTTTGGCCCGGGCACCAAAGTGGATATTAAAH15-  51 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCACCTATAGCATGGGCTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCGATACCGATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAACGCACCATGGTGCGCGATCCGCGCTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGA CCGTGAGCAGC H15-  52 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC VlCTGAGCCCGGGCGAACGCGCGACCCTGAGCTGCCG CGCGAGCCAGAGCGTGAGCAGCTATCTGGCGTGGTATCAGCAGCGCCTGGGCCAGAGCCCGCGCCTGCTGATTTATGATGCGAGCAGCCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCAACCTGGTGA CCTTTGGCCAGGGCACCCGCCTGGAAATTAAAF11-  53 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCAACTATATGATGACCTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCGGCATTTATCCGAGCGGCGGCTTTACCCAGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGACCTATTATTGCGCGCGCGATGCGAGCGATGTGTGGCTGCGCTTTCGCGGCGGCGGCGCGTTTGATATTTGGGGCCAGGGCACCA TGGTGACCGTGAGCAGC F11-  54 DNAGATATTCAGATGACCCAGAGCCCGACCAGCCTGAGC VlGCGAGCGTGGGCGATCGCGTGGCGATTACCTGCCGCGCGAGCCAGAGCATTGATACCTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGTTTGATGATCTGCCGCTGACCTT TGGCCCGGGCACCCGCGTGGATATTAAA K12- 55 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCCGCTATATTATGCATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCCTGACCAGCTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAATTTGAAAACGCGTATCATTATTATTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGACC GTGAGCAGC K12-  56 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC VlGCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGCGCGAGCGGCGATATTGGCAACGCGCTGGGCTGGTATCAGCAGAAACCGGGCAAAGCGCCGCGCCTGCTGATTAGCGATGCGAGCACCCTGCAGAGCGGCGTGCCGCTGCGCTTTAGCGGCAGCGGCAGCGGCACCGAATTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCTGCAGGGCTATAACTATCCGCGCAC CTTTGGCCAGGGCACCAAACTGGAAATTCGCO15-  57 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCCGCTATATTATGCATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCCTGACCAGCTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAATTTGAAAACGCGTATCATTATTATTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGACC GTGAGCAGC O15-  58 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC VlGCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGCGCGAGCGGCGATATTGGCAACGCGCTGGGCTGGTATCAGCAGAAACCGGGCAAAGCGCCGCGCCTGCTGATTAGCGATGCGAGCACCCTGCAGAGCGGCGTGCCGCTGCGCTTTAGCGGCAGCGGCAGCGGCACCGAATTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCTGCAGGGCTATAACTATCCGCGCAC CTTTGGCCAGGGCACCAAACTGGAAATTCGCA08-  59 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCGAATATGGCATGATTTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCTTTATTAGCCCGAGCGGCGGCACCACCTTTTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACTTTAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGGCGGCGGCAACTGGAACCATCGCCGCGCGCTGAACGATGCGTTTGATATTTGGGGCCAGGGCACCAT GGTGACCGTGAGCAGC A08-  60 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC VlGCGAGCGTGGGCGATCGCATTACCATTACCTGCCGCGCGAGCCAGGCGATTCGCGATGATTTTGGCTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGCGGCGAGCAGCCTGCAGAGCGGCGTGCCGAGCC GCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCACCCCGCTGACC TTTGGCGGCGGCACCAAAGTGGAAATTAAAE12-  61 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG VhCAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGCGAGCGGCTTTACCTTTAGCACCTATAGCATGGGCTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTAGCCCGAGCGGCGGCGATACCGATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAACGCACCATGGTGCGCGATCCGCGCTATTATGGCATGGATGTGTGGGGCCAGGGCACCACCGTGA CCGTGAGCAGC E12-  62 DNAGATATTCAGATGACCCAGAGCCCGGCGACCCTGAGC VlCTGAGCCCGGGCGAACGCGCGACCCTGAGCTGCCG CGCGAGCCAGAGCGTGAGCAGCTATCTGGCGTGGTATCAGCAGCGCCTGGGCCAGAGCCCGCGCCTGCTGATTTATGATGCGAGCAGCCGCGCGACCGGCATTCCGGCGCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCAACCTGGTGA CCTTTGGCCAGGGCACCCGCCTGGAAATTAAAY11  63 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1W-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATTGGGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  64 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1W-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA N11 65 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 0D-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC S11GAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGG 1N-GTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT VhGAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCN11  66 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0D-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG S11GCGAGCCAGGATATTAGCAACTATCTGAACTGGTATC 1N-AGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTA VlTGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGGATAACCTGCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y10 67 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 9W-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTGGTATTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY10  68 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 9W-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 69 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 0S-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATAGCTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  70 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0S-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA S11 71 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1N-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC F11GAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGG 2L-GTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT VhGAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCS11  72 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1N-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG F11GCGAGCCAGGATATTAGCAACTATCTGAACTGGTATC 2L-AGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTA VlTGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAACCTGCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA P10 73 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 7G-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCGGCTATTATTATTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCP10  74 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 7G-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 75 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 0R-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATCGCTATGGCATGGATG TGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  76 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0R-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 77 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 0W-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTGGTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  78 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0W-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 79 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 0N-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATAACTATGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  80 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0N-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 81 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1Q-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATCAGGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  82 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1Q-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 83 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1K-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATAAAGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  84 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1K-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 85 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1V-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATTATGTGGGCATGGATGT GTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  86 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1V-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA Y11 87 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 0A-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC VhGAGCGGCTTTACCTTTAGCCAGTATGGCATGGATTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCGGCATTGGCCCGAGCGGCGGCAGCACCGTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCACCCGCGGCGGCCCGTATTATGCGTATGGCATGGATG TGTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCY11  88 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 0A-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG VlGCGAGCCAGGATATTAGCAACTATCTGAACTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGGCGAACAGCTTTCCGGTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA M00 89 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC G16-GAGCGGCTTTACCTTTAGCACCTATTGGATGACCTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTTGGAGCAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAAGTGGGCGCGGCGGGCTTTGCGTTTGATA TTTGGGGCCAGGGCACCATGGTGACCGTGAGCAGCM00  90 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG G16-GCGAGCCAGGATATTAGCAACTATCTGAACTGGTATC VlAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGAGCAGCAGCACCCCGCTGACCTT TGGCGGCGGCACCAAAATGGAAATTAAA M00 91 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC J11-GAGCGGCTTTACCTTTAGCACCTATGAAATGAACTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCTGGATTGGCCCGAGCGGCGGCTTTACCTTTTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGAAAGATAAAGCGGTGGCGGGCATGGGCGAAGCGTTTGATATTTGGGGCCAGGGCACCATGGTGACCGTGA GCAGC M00  92 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 1-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG J11-GCGAGCCAGGATATTAGCATTTATCTGAACTGGTATC VlAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAACGTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCAGCCGGAAGATATTGCGACCTATTATTGCCAGCAGTTTTATAACCTGCCGCTGACCTT TGGCGGCGGCACCAAAGTGGAAATTAAA M02 93 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 8-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC H17-GAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC M02 94 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC 8-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC H17-GCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTAT VlCAGCAGCGCCCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCACCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAAACTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTGC GTTTGGCCAGGGCACCCGCCTGGAAATTAAAM06  95 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 7-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC F04-GAGCGGCTTTACCTTTAGCCCGTATGATATGTATTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCTATATTTGGAGCAGCGGCGGCATTACCCAGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCCATGCGAGCTATTATGATAGCAGCGGCCGCCCGGATGCGTTTGATATTTGGGGCCAGGGCACCATGGT GACCGTGAGCAGC M06  96 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 7-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC F04-GCGAGCCAGAGCATTAGCAGCTATGTGAACTGGTATC VlAGCAGAAACCGGGCAAAGCGCCGAACCTGCTGATTTATGCGGCGAGCAGCCTGGAAAGCGGCGTGCCGAGCC GCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCACCCCGTATACC TTTGGCCAGGGCACCAAACTGGATATTAAA M06 97 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 7-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC C04-GAGCGGCTTTACCTTTAGCCATTATAGCATGCAGTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCAGCATTAGCCCGAGCGGCGGCTATACCATGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGATGTATTATTGCGCGCGCGAAAAAGCGAGCGATCTGAGCGGCACCTATAGCGAAGCGCTGGATTATTGGGGCCAGGGCACCCTGG TGACCGTGAGCAGC M06  98 DNAGATATTCAGATGACCCAGAGCCCGAGCAGCCTGAGC 7-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCAG C04-GCGAGCCAGGATATTGATTATTATCTGAACTGGTATC VlAGCAGCAGCCGGGCAAAGCGCCGCAGCTGCTGATTTATGATGCGAGCAACCTGGAAACCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCTTTACCATTAGCAGCCTGCATCCGGAAGATTTTGCGACCTATTATTGCCAGCAGTATCATACCCTGCCGCCGCTGAC CTTTGGCGGCGGCACCAAAGTGGATATTAAAM07  99 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG 1-CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC F17-GAGCGGCTTTACCTTTAGCCCGTATTGGATGCATTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGTGAGCAGCATTTATAGCAGCGGCGGCTGGACCGATTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGCGCGAAGGCGTGGCGGGCACCAACGATGCGTTTGATATTTGGGGCCAGGGCACCATGGTGACCGTGAGCA GC M07 100 DNAGATATTCAGATGACCCAGAGCCCGCTGAGCCTGAGC 1-GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC F17-GCGAGCCAGAGCATTAGCAGCTATCTGAACTGGTATC VlAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGCGGCGAGCAGCCTGCAGAGCGGCGTGCCGAGCC GCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGAGCTATAGCACCCCGCCGTGG ACCTTTGGCCAGGGCACCAAAGTGGAAATTAAAH17- 101 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG R47CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC K-VhGAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC H17-102 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC R47GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC K-VlGCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCACCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAAACTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTGCG TTTGGCCAGGGCACCCGCCTGGAAATTAAAH17- 103 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG T69CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC S-VhGAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC H17-104 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC T69GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC S-VlGCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTATCAGCAGCGCCCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCAGCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAAACTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTGC GTTTGGCCAGGGCACCCGCCTGGAAATTAAAH17- 105 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG N10CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC 0D-GAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC H17-106 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC N10GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC 0D-GCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTAT VlCAGCAGCGCCCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCACCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTGC GTTTGGCCAGGGCACCCGCCTGGAAATTAAAH17- 107 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG A11CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC 5T-GAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGG VhGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC H17-108 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC A11GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC 5T-GCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTAT VlCAGCAGCGCCCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCACCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAAACTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTAC CTTTGGCCAGGGCACCCGCCTGGAAATTAAAH17- 109 DNA GAAGTGCAGCTGCTGGAAAGCGGCGGCGGCCTGGTG R47CAGCCGGGCGGCAGCCTGCGCCTGAGCTGCGCGGC K-VhGAGCGGCTTTACCTTTAGCGATTATGAAATGGCGTGGGTGCGCCAGGCGCCGGGCAAAGGCCTGGAATGGGT GAGCAGCATTGTGCCGAGCGGCGGCTGGACCCTGTATGCGGATAGCGTGAAAGGCCGCTTTACCATTAGCCGCGATAACAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGCGCGCGGAAGATACCGCGGTGTATTATTGCGCGACCTGGGGCGATAGCTGGGGCTTTGATTTTTGGG GCCAGGGCACCCTGGTGACCGTGAGCAGC H17-110 DNA GATATTCAGATGACCCAGAGCCCGAGCAGCGTGAGC R47GCGAGCGTGGGCGATCGCGTGACCATTACCTGCCGC K-VlGCGAGCCAGGGCATTAGCAGCTGGCTGGCGTGGTATCAGCAGAAACCGGGCAAAGCGCCGAAACTGCTGATTTATGATGCGAGCACCCTGCAGAGCGGCGTGCCGAGCCGCTTTAGCGGCAGCGGCAGCGGCACCGATTTTACCCTGACCATTAACAGCCTGCAGCCGGAAGATTTTGCGACCTATTATTGCCAGCAGGCGGATAGCTTTCCGATTGCG TTTGGCCAGGGCACCCGCCTGGAAATTAAA M00111 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYIMHWV 9-RQAPGKGLEWVSSISPSGGLTSYADSVKGRFTISRDN G02-SKNTLYLQMNSLRAEDTAVYYCAREFENAYHYYYYGM Vh DVWGQGTTVTVSS M00 112 PRTDIQMTQSPSSLSASVGDRVTITCRASGDIGNALGWYQ 9-QKPGKAPRLLISDASTLQSGVPLRFSGSGSGTEFTLT G02-ISSLQPEDFATYYCLQGYNYPRTFGQGTKLEIR Vl G16- 113 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSWYPMQWV VhRQAPGKGLEWVSGISSSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDWGYSNYVMDLGL DYWGQGTLVTVSS G16- 114 PRTDIQMTQSPATLSLSAGERATLSCRASQTVSSSLAWYQ VlHKPGQAPRLLIYETSNRATGIPARFSGSGSGTDFTLT ISSLEPEDFAVYYCQHRSNWPPTFGPGTKVDIKG11- 115 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYSMGWV VhRQAPGKGLEWVSSISPSGGDTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERTMVRDPRYYGM DVWGQGTTVTVSS G11- 116 PRTDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ VlQRLGQSPRLLIYDASSRATGIPARFSGSGSGTDFTLT ISSLQPEDFATYYCQQSYSNLVTFGQGTRLEIKM01 117 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYYMKWV 4-RQAPGKGLEWVSSISPSGGFTSYADSVKGRFTISRDN G02-SKNTLYLQMNSLRAEDTAVYYCAREFENAYHYYYYGM Vh DVWGQGTTVTVSS M01 118 PRTDIQMTQSPSSVSASVGDRVTITCRASQDINIWLAWYQ 4-QKPGKAPKLLISAASTVQSGVPSRFSGSGSGTDFTLT G02-INTLQPDDFATYYCQQAASFPLTFGGGTKVEMK Vl M01 119 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYSMGWV 3-RQAPGKGLEWVSSISPSGGDTDYADSVKGRFTISRDN J04-SKNTLYLQMNSLRAEDTAVYYCARERTMVRDPRYYGM Vh DVWGQGTTVTVSS M01 120 PRTDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ 3-QRLGQSPRLLIYDASSRATGIPARFSGSGSGTDFTLT J04-ISSLQPKDFATYYCQQSYSNLVTFGQGTRLEIK Vl A10- 121 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSWYPMQWV VhRQAPGKGLEWVSGISSSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDWGYSNYVMDLGL DYWGQGTLVTVSS A10- 122 PRTDIQMTQSPATLSLSAGERATLSCRASQTVSSSLAWYQ VlHKPGQAPRLLIYETSNRATGIPARFSGSGSGTDFTLT ISSLEPEDFAVYYCQHRSNWPPTFGPGTKVDIKM10- 123 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYPMQWV VhRQAPGKGLEWVSGISSSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDWGYSNYVMDLGL DYWGQGTLVTVSS M10- 124 PRTDIQMTQSPATLSLSAGERATLSCRASQTVSSSLAWYQ VlHKPGQAPRLLIYETSNRATGIPARFSGSGSGTDFTLT ISSLEPEDFAVYYCQHRSNWPPTFGPGTKVDIKH15- 125 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYSMGWV VhRQAPGKGLEWVSSISPSGGDTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERTMVRDPRYYGM DVWGQGTTVTVSS H15- 126 PRTDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ VlQRLGQSPRLLIYDASSRATGIPARFSGSGSGTDFTLT ISSLQPEDFATYYCQQSYSNLVTFGQGTRLEIKF11- 127 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYMMTWV VhRQAPGKGLEWVSGIYPSGGFTQYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARDASDVWLRFRGGG AFDIWGQGTMVTVSS F11- 128 PRTDIQMTQSPTSLSASVGDRVAITCRASQSIDTYLNWYQ VlQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT ISSLQPEDIATYYCQQFDDLPLTFGPGTRVDIKK12- 129 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYIMHWV VhRQAPGKGLEWVSSISPSGGLTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREFENAYHYYYYGM DVWGQGTTVTVSS K12- 130 PRTDIQMTQSPSSLSASVGDRVTITCRASGDIGNALGWYQ VlQKPGKAPRLLISDASTLQSGVPLRFSGSGSGTEFTLT ISSLQPEDFATYYCLQGYNYPRTFGQGTKLEIRO15- 131 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYIMHWV VhRQAPGKGLEWVSSISPSGGLTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREFENAYHYYYYGM DVWGQGTTVTVSS O15- 132 PRTDIQMTQSPSSLSASVGDRVTITCRASGDIGNALGWYQ VlQKPGKAPRLLISDASTLQSGVPLRFSGSGSGTEFTLT ISSLQPEDFATYYCLQGYNYPRTFGQGTKLEIRA08- 133 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSEYGMIWV VhRQAPGKGLEWVSFISPSGGTTFYADSVKGRFTISRDNFKNTLYLQMNSLRAEDTAVYYCARGGGNWNHRRALND AFDIWGQGTMVTVSS A08- 134 PRTDIQMTQSPSSLSASVGDRITITCRASQAIRDDFGWYQ VlQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLT ISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKE12- 135 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYSMGWV VhRQAPGKGLEWVSSISPSGGDTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARERTMVRDPRYYGM DVWGQGTTVTVSS E12- 136 PRTDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ VlQRLGQSPRLLIYDASSRATGIPARFSGSGSGTDFTLT ISSLQPEDFATYYCQQSYSNLVTFGQGTRLEIKY11 137 PRT EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 1W-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYWGMDVWG QGTTVTVSS Y11 138 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 1W-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK N11 139 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 0D-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN S11SKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWG 1N- QGTTVTVSS Vh N11 140 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0D-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT S11ISSLQPEDIATYYCQQADNLPVTFGGGTKVEIK 1N- Vl Y10 141 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 9W-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYWYYGMDVWG QGTTVTVSS Y10 142 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 9W-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 143 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 0S-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYSYGMDVWG QGTTVTVSS Y11 144 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0S-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK S11 145 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 1N-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN F11SKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWG 2L- QGTTVTVSS Vh S11 146 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 1N-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT F11ISSLQPEDIATYYCQQANNLPVTFGGGTKVEIK 2L- Vl P10 147 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 7G-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGGYYYYGMDVWG QGTTVTVSS P10 148 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 7G-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 149 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 0R-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYRYGMDVWG QGTTVTVSS Y11 150 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0R-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 151 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 0W-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYWYGMDVWG QGTTVTVSS Y11 152 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0W-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 153 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 0N-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYNYGMDVWG QGTTVTVSS Y11 154 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0N-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 155 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 1Q-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYQGMDVWG QGTTVTVSS Y11 156 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 1Q-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 157 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 1K-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYKGMDVWG QGTTVTVSS Y11 158 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 1K-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 159 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 1V-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYVGMDVWG QGTTVTVSS Y11 160 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 1V-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK Y11 161 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWV 0A-RQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDN VhSKNTLYLQMNSLRAEDTAVYYCTRGGPYYAYGMDVWG QGTTVTVSS Y11 162 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 0A-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT VlISSLQPEDIATYYCQQANSFPVTFGGGTKVEIK M00 163 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYWMTWV 1-RQAPGKGLEWVSSIWSSGGWTLYADSVKGRFTISRDN G16-SKNTLYLQMNSLRAEDTAVYYCAREVGAAGFAFDIWG Vh QGTMVTVSS M00 164 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQ 1-QKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFT G16-ISSLQPEDIATYYCQQSSSTPLTFGGGTKMEIK Vl M00 165 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSTYEMNWV 1-RQAPGKGLEWVSWIGPSGGFTFYADSVKGRFTISRDN J11-SKNTLYLQMNSLRAEDTAVYYCAKDKAVAGMGEAFDI Vh WGQGTMVTVSS M00 166 PRTDIQMTQSPSSLSASVGDRVTITCQASQDISIYLNWYQ 1-QKPGKAPKLLIYDASNVETGVPSRFSGSGSGTDFTFT J11-ISSLQPEDIATYYCQQFYNLPLTFGGGTKVEIK Vl M02 167 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV 8-RQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN H17-SKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG Vh TLVTVSS M02 168 PRTDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ 8-QRPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLT H17-INSLQPENFATYYCQQADSFPIAFGQGTRLEIK Vl M06 169 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSPYDMYWV 7-RQAPGKGLEWVSYIWSSGGITQYADSVKGRFTISRDN F04-SKNTLYLQMNSLRAEDTAVYYCARHASYYDSSGRPDA Vh FDIWGQGTMVTVSS M06 170 PRTDIQMTQSPSSLSASVGDRVTITCRASQSISSYVNWYQ 7-QKPGKAPNLLIYAASSLESGVPSRFSGSGSGTDFTLT F04-ISSLQPEDFATYYCQQSYSTPYTFGQGTKLDIK Vl M06 171 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSHYSMQWV 7-RQAPGKGLEWVSSISPSGGYTMYADSVKGRFTISRDN C04-SKNTLYLQMNSLRAEDTAMYYCAREKASDLSGTYSEA Vh LDYWGQGTLVTVSS M06 172 PRTDIQMTQSPSSLSASVGDRVTITCQASQDIDYYLNWYQ 7-QQPGKAPQLLIYDASNLETGVPSRFSGSGSGTDFTFT C04-ISSLHPEDFATYYCQQYHTLPPLTFGGGTKVDIK Vl M07 173 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSPYWMHWV 1-RQAPGKGLEWVSSIYSSGGWTDYADSVKGRFTISRDN F17-SKNTLYLQMNSLRAEDTAVYYCAREGVAGTNDAFDIW Vh GQGTMVTVSS M07 174 PRTDIQMTQSPLSLSASVGDRVTITCRASQSISSYLNWYQ 1-QKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLT F17-ISSLQPEDFATYYCQQSYSTPPWTFGQGTKVEI Vl H17- 175 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV R47RQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN K-VhSKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG TLVTVSS H17- 176 PRTDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ R47QKPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLT K-VlINSLQPENFATYYCQQADSFPIAFGQGTRLEIK H17- 177 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV T69RQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN S-VhSKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG TLVTVSS H17- 178 PRTDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ T69QRPGKAPKLLIYDASSLQSGVPSRFSGSGSGTDFTLT S-VlINSLQPENFATYYCQQADSFPIAFGQGTRLEIK H17- 179 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV N10RQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN 0D-SKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG Vh TLVTVSS H17- 180 PRTDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ N10QRPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLT 0D-INSLQPEDFATYYCQQADSFPIAFGQGTRLEIK Vl H17- 181 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV A11RQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN 5T-SKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG Vh TLVTVSS H17- 182 PRTDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ A11QRPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLT 5T-INSLQPENFATYYCQQADSFPITFGQGTRLEIK Vl H17- 183 PRTEVQLLESGGGLVQPGGSLRLSCAASGFTFSDYEMAWV R47RQAPGKGLEWVSSIVPSGGWTLYADSVKGRFTISRDN K-VhSKNTLYLQMNSLRAEDTAVYYCATWGDSWGFDFWGQG TLVTVSS H17- 184 PRTDIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQ R47QKPGKAPKLLIYDASTLQSGVPSRFSGSGSGTDFTLT K-VlINSLQPEDFATYYCQQADSFPIAFGQGTRLEIK

Example 4: Determination of the Anti-Aggregatory Activity of the FXIaAntibody

For the measurement of platelet activation under flow conditions, glassslides (Menzel-Glaser SUPERFROST 76×26 mm; Gerhard Menzel GmbH,Braunschweig, Germany) were coated with collagen (150 μg/ml) overnightat 4° C., followed by blocking with BSA (5 mg/ml) prior to assembly intoa flow system on the stage of a Zeiss Axiovert 135 microscope (CarlZeiss, Göttingen, Germany). Citrated whole blood was incubated with GPRP(3 mM final) and vehicle or FXI antibodies for 10 min at 37° C. Afterthe addition of CaCl₂ (5 mM), blood was immediately perfused over thecollagen-coated slide at the initial shear rate of 1000 s⁻¹ for 5 min.After the perfusion of whole blood as described above, post-chamberwhole blood was collected into sodium citrate (1:10 vol/vol) at each 1min. Pre-chamber blood was also sampled and treated with or withoutTRAP6 as positive control (10 μg/ml) for 5 min.

Pre- and post-chamber blood samples were diluted in Cell Wash (BDBiosciences, Heidelberg, Germany) and incubated with antibodies for 20min at 4° C. Antibody reaction was stopped by adding ice cold-Cell Washand all samples were kept on ice until measurement. 10000 singleplatelets were determined with the positivity of the FITC-conjugatedplatelet marker (CD41a or CD61a) and the characteristic light scatterpatterns by flow cytometry (FACSCalibur; BD Biosciences, Heidelberg,Germany). For CD62P expression, single platelets were gated to aseparate scatter plot with a PE-CD62P fluorescence threshold which wasverified with unlabeled control samples. The platelet population abovethe threshold was considered activated and quantified. Plateletmicroaggregates were defined with the arbitrary thresholds for ForwardScatter (FSC) and FITC-fluorescence.

Example 5: FeCl₂ Induced Thrombosis and Ear Bleeding Time in Rabbits

The antithrombotic activity of 076D-M007-H04, 076D-M007-H04-CDRL3-N110Dand 076D-M028-H17 was determined in an arterial thrombosis model. 15minutes after an i.v. bolus administration of 076D-M007-H04 (0.5 mg/kg,1 mg/kg, 2 mg/kg), 076D-M007-H04-CDRL3-N110D (0.1 mg/kg, 0.3 mg/kg, 1mg/kg) or 076D-M028-H17 (0.075 mg/kg, 0.15 mg/kg, 0.3 mg/kg) thrombosiswas induced by chemical damage of a carotid artery by ferric chloride inrabbits. Male rabbits (Crl:KBL (NZVV)BR, Charles River) wereanaesthetized with a mixture of xylazine and ketamine (Rompun, Bayer 5mg/kg and Ketavet Pharmacia & Upjohn GmbH, 40 mg/kg body weight) givenby i.m. injection. Supplemental anesthesia was administered by infusionof the anesthetic mixture in the marginal vein of the right ear. Afterexposure of the right common carotid artery vascular damage was producedby placing a piece of blotting paper (10 mm×10 mm) on a strip ofParafilm® (25 mm×12 mm) under the right common carotid artery in a waythat the blood flow was not affected. The blotting paper was saturatedwith 100 μl FeCl₂ (Iron(II) chloride tetrahydrate), 13% in A. dest,Sigma). After 5 minutes the filter paper was removed, and the vessel wasrinsed twice with 0.9% NaCl. 30 minutes after the injury the carotidartery was removed, the thrombus withdrawn and weighed immediately. 5-7animals were used for each group. The ear bleeding time was determined 2minutes after the FeCl₂-injury. The left ear was shaved and astandardized incision (3 mm long) was made with a surgical blade (number10-150-10, Martin, Tuttlingen, Germany) parallel to the long axis of theear. Care was taken to avoid damage of visible blood vessels. Theincision sites were blotted at 30 sec intervals with filter paper,carefully avoiding contact with the wound. The bleeding time wasdetermined by measuring the time from the incision until blood no longerstained the filter paper.

Example 6: Determination of the FeCl₂ Induced Thrombosis and EarBleeding Time in Rabbits

076D-M007-H04 dose-dependently reduces the thrombus weight and does notprolong the ear bleeding time as shown in FIG. 14. FIG. 15 demonstratesthe antithrombotic effect of 076D-M007-H04-CDRL3-N110D without anincrease in ear bleeding time. In FIG. 16 the antithrombotic effect andno bleeding time prolongation of 076D-M028-H17 is shown.

Example 7: Complex Formation, Crystallization and X-Ray StructureDetermination of Fab 076D-M007-H04:FXIa Complex

Complex Formation and Crystallization.

FXIa C500S (amino acids 388-625) was purchased by ProterosBiostructures. Purified Fab 076D-M007-H04 was mixed in an 1:1 ratio withFXIa C500S. To allow complex formation the solution was stored for 18hours on ice. The complex solution was loaded on a Superdex 200 HR 16/60column and was further concentrated to a final concentration of 20 mg/mlin 20 mM Tris/HCl at pH 7.5 and 75 mM NaCl. Crystals of the proteincomplex comprising Fab 076D-M007-H04 and FXIa C500S were grown at 20° C.using the sitting-drop method and crystallized by mixing equal volumesof protein complex solution and well solution (100 mM TRIS pH 8.25,0.05% PEG20000, and 2.4M NH4SO4 as precipitant. A rosette like crystalappeared after approximately five days.

Data Collection and Processing.

Crystal was flash-frozen in liquid nitrogen without use of cryo-buffer.Data of crystal was collected at beamline BL14.1, BESSY synchrotron(Berlin) on a MAR CCD detector. Data was indexed and integrated with XDS(Kabsch, W. (2010) Acta Cryst. D66, 125-132), prepared for scaling withPOINTLESS, and scaled with SCALA (P. R. Evans, (2005) Acta Cryst. D62,72-82). The crystal diffracted up to 2.7 Å and possesses orthorhombicspace group P2(1)22(1) with cell constant a=61.9, b=70.7, c=185.9 andone Fab 076D-M007-H04:FXIa C500S complex in the asymmetric unit.

Structure Determination and Refinement.

The complex-structure of FXIa and the monoclonal antibody Fab076D-M007-H04 was solved by molecular replacement in different steps.First the H-chain was located using BALBES (F. Long, A. Vagin, P. Youngand G. N. Murshudov (2008) Acta Cryst. D64, 125-132), with pdb code 3GJEas search model. Then FXIa C500S was added using program MolRep with aninternal FXIa crystal structure as search model. Initial refinement withREFMAC5.5 (G. N. Murshudov et al. (1997) Acta Cryst. D53, 240-255)results in R1=39.4% and Rfree=44.1%. Finally, the H-chain was locatedusing the L-chain of pdb entry 31DX as search model and fixedcoordiantes of the initially refined H-chain and FXIa C500S solution.Iterative rounds of model building with COOT (P. Emsley et al. (2010)Acta Cryst. D66:486-501) and maximum likelihood refinement usingREFMAC5.5 completed the model. Data set and refinement statistics aresummarized in table 10.

TABLE 10 Data set and refinement statistics for Fab 076D-M007-H04:FXIacomplex. Wavelength 0.91823 Å Resolution (highest shell) 33.03-2.70(2.84-2.70) Å Reflections (observed/unique) 110602/16132Completeness^(a) 99.8% (99.15%) I/s^(a) 5.61 (1.79) R_(merge) ^(a,b)0.12 (0.43) Space group P2(1)22(1) Unit cell parameters a  61.94 Å b 87.68 Å c 185.89 Å R_(cryst) ^(c) 0.228 R_(free) ^(d) 0.305 Wilsontemperature factor  51.7 A² RMSD bond length^(e)   0.022 Å RMSD bondangles  1.95° Protein atoms 5042     Water and solvent molecules 34   ^(a)The values in parentheses are for the high resolution shell.^(b)R_(merge) = Σhk1|I_(hk1) −

Ihk1

/Σhk1

I_(hk1)

 where I_(hk1) is the intensity of reflection hk1 and

I_(hk1)

 is the average intensity of multiple observations. ^(c)R_(cryst) = Σ|F_(obs) − F_(calc)|/Σ F_(obs) where F_(obs) and F_(calc) are theobserved and calculated structure factor amplitudes, respectively.^(d)5% test set ^(e)RMSD, root mean square deviation from the parameterset for ideal stereochemistry

Example 8: X-Ray Structure-Based Epitope Mapping

The complex of Fab 076D-M007-H04 and FXIa C500S (FIG. 17) crystallizedas one copy of the complex per asymmetric unit. Residues of Fab076D-M007-H04 (paratope) in contact with FXIa C500S (epitope) weredetermined and are listed in table Xa and Xb. Buried surface wasanalysed with the CCP4 program AREAIMOL (P. J. Briggs (2000) CCP4Newsletter No. 38) and residues showing a total area difference whencalculated with bound and without bound Fab 076D-M007-H04 (table 11a)and FXIa C500S (table 11b), respectively

TABLE 11a Residues of FXIa in contact with Fab 076D-M007-H04 Epitope:Area Residue Nr Differences HIS A 406  −8.30 PRO A 410  −55.30 THR A 411 −60.10 GLN A 412  −2.10 ARG A 413  −35.60 HIS A 414  −4.00 ASN A 450 −12.40 GLN A 451  −26.90 SER A 452  −48.20 ILE A 454  −1.50 LYS A 455 −32.40 ARG A 522  −29.90 LYS A 523  −53.00 LEU A 524 −105.20 ARG A 525−171.10 ASP A 526  −6.20 LYS A 527 −120.10 ILE A 528  −28.60 GLN A 529 −41.30 ASN A 530  −58.50 THR A 531  −6.30

TABLE 11b Residues of Fab 076D-M007-H04 in contact with FXIa Paratrope:Area Residue Nr Differences SER L 32  −4.50 ASN L 32  −15.90 TYR L 34 −87.20 TYR L 51  −21.80 ASP L 52  −18.30 ASN L 55  −38.10 THR L 58 −33.50 ALA L 93  −12.50 ASN L 94  −36.80 SER L 95  −11.80 PHE L 96 −41.30 VAL L 98  −0.30 THR H 28  −27.80 GLN H 31  −60.20 TYR H 32 −19.00 GLYH 33  −15.00 ASP H 35  −3.90 GLY H 50  −5.60 ILE H 51  −7.20GLY H 52  −10.20 PRO H 53  −13.30 SER H 57  −3.00 VAL H 59  −0.70 GLY H99  −8.80 GLY H 100  −5.50 PRO H 101  −3.10 TYR H 102 −149.50 TYR H 103−103.50 TYR H 104  −10.20 TYR H 105  −52.10

In summary, FXIa C500S epitope is formed by the following residues:

HIS A 406, PRO A 410, THR A 411, GLN A 412. ARG A 413, HIS A 414, ASN A450, GLN A 451, SER A 452, ILE A 454, LYS A 455, ARG A 522, LYS A 523,LEU A 524, ARG A 525, ASP A 526, LYS A 527, ILE A 528, GLN A 529, ASN A530, THR A 531

Fab 076D-M007-H04 acts as a allosteric competitive inhibitor. It is notblocking the active site of FXIa directly but binds adjacent to it. Thisadjacent binding triggers a re-arrangement of parts of active site ofFXIa hindering natural substrates to bind to activated FXIa (FIG. 18).

In contrast, Fab 076D-M007-H04 does not bind zymogen FXI. In thereported x-ray structure of zymogen FXI (pdb entry 2F83) various loopsbuilding up the active site as well as the epitope to Fab 076D-M007-H04are not properly ordered. Especially the epitope region is wellstructured in the Fab 076D-M007-H04:FXIa C500S complex.

Example 9: Hydrogen/Deuterium-Exchange Mass Spectrometry-Based EpitopeMapping

A different analysis of Epitope mapping has been performed by thecontract research organization ExSAR [ExSAR Corporation; 11 Deer ParkDrive, Suite 103; Monmouth Junction, N.J. 08852; USA]. In this case, theinteractions of FXIa C500S (amino acids 388-625; purchased by ProterosBiostructures) and the purified Fabs of 076D-M007-H04 and 076D-M049-O15,respectively, have been analyzed by the differential hydrogen/deuteriumexchange mass spectrometry method [for overview see Percy A J, Rey M,Burns K M, Schriemer D C. (2012) Probing protein interactions withhydrogen/deuterium exchange and mass spectrometry—a review. Anal ChimActa. 721:7-21]. Thereby, differences in the deuteration level of morethan 10% indicates a strong protection by the Fab of the correspondingantigen. Values between 5 and 10% indicate weak binding, differences inthe deuteration level of below 5% indicates no protection at al.

Table 12a and table 12b are summarizing the residues of Fab076D-M007-H04 and of Fab 076D-M049-O15 in contact with FXIa,respectively.

TABLE 12a Residues of Fab 076D-M007-H04 in contact with FXIa averagedeuteration Residue Nr level difference (%) THR 408 5-10 SER 409 5-10PRO 410 5-10 THR 411 5-10 GLN 412 5-10 ARG 413 5-10 HIS 414 5-10 LEU 4155-10 CYS 416 5-10 GLY 417 5-10 GLY 418 5-10 SER 419 5-10 ILE 420 5-10ILE 421 5-10 GLY 422 5-10 ASN 423 5-10 GLN 424 5-10 VAL 444 >10 TYR445 >10 SER 446 >10 GLY 447 >10 ILE 448 >10 LEU 449 >10 ASN 450 >10 GLN451 >10 SER 452 >10 ILE 454 >10 LYS 455 >10 THR 517 >10 GLY 518 >10 TRP519 >10 LYS 523  34 LEU 524  34 ARG 525  34 ASP 56  34 LYS 527  34 ILE528  34 GLN 529  34 ASN 530  34 THR 531  34 LEU 532  34 GLN 533  34

TABLE 12b Residues of Fab 076D-M049-O15 in contact with FXIa averagedeuteration Residue Nr level difference (%) THR 517 5-10 GLY 518 5-10TRP 519 5-10 LYS 523 >10 LEU 524 >10 ARG 525 >10 ASP 526 >10 LYS 527 >10ILE 528 >10 GLN 529 >10 ASN 530 >10 THR 531 >10 LEU 532 >10 GLN 533 >10TYR 563 5-10 ARG 564 5-10 GLU 565 5-10 GLY 566 5-10 GLY 567 5-10 LYS 5685-10 ASP 569 5-10 ALA 570 5-10 CYS 571 5-10 LYS 572 5-10 GLY 573 5-10ASP 574 5-10 SER 575 5-10 GLY 576 5-10 GLY 577 5-10 PRO 578 5-10 LEU 5795-10 SER 580 5-10 CYS 581 5-10 LYS 582 5-10 HIS 583 5-10 ASN 584 5-10GLU 585 5-10 VAL 586 5-10 TRP 587 5-10 HIS 588 5-10 LEU 589 5-10 VAL 5905-10 GLY 591 5-10 SER 594 >10 TRP 595 >10 GLY596 >10 GLU 597 >10 GLY598 >10 CYS 599 >10 ALA 600 >10 GLU 603 >10 ARG 604 >10 PRO 605 >10 GLY607 >10 VAL 608 >10 TYR 609 >10

These data clearly show that covering an epitope of 200 amino acidswithin FXIa (amino acids 408-609 of FXIa C500S) leads to an inhibitionof FXIa proteolytic activity.

Example 10: Functional Neutralization of FXIa by Antibodies of thisInvention

Human FXIa (Haematologic Technologies, Inc., catalogue numberHCXIA-0160) activity is determined by measuring the cleavage of aspecific, fluorogenically-labeled substrate (I-1575, Bachem, finalconcentration 25 μM) and the fluorescence is monitored continuously at360/465 nm using a SpectraFluorplus Reader (Tecan). For testing theinhibitory activity, the antibodies are pre-incubated for 60 minutes at37° C. with a final concentration of 10 nM of FXIa in a buffercontaining 50 mM Tris/HCl, 100 mM NaCl, 5 mM CaCl2 and 0.1% BSA.Following this incubation step, the substrate 1-1575 is added, and thesignals from the reaction are measured. Data are analyzed using theGraphPadPrism software as shown in FIG. 1, FIG. 2, FIG. 3, and in FIG.4. Data are given as mean±SEM, n=4.

For some experiments instead of the full length human FXIa (HaematologicTechnologies, Inc., catalogue number HCXIA-0160) the isolated catalyticdomain of FXIa C500S (amino acids 388-625; purchased by ProterosBiostructures) is used. All other conditions are as described above.

Example 11: Functional Neutralization of the Conversion of FXI into itsActive Form, FXIa, by Antibodies of this Invention

For testing the inhibition of the conversion of FXI (HaematologicTechnologies, Inc., catalogue number HCXIA-0150) into its active formFXIa by FXIIa or Thrombin (Thrombin is IIa), 10 nM of human FXI isincubated in 50 mM Tris/HCl, 100 mM NaCl, 5 mM CaCl2 und 0.1% BSA withdifferent concentrations of the antibodies for 1 hour at 37° C. In anext step, 10 nM final concentration of human FXIIa (Enzyme Research,catalogue number HFXIla 1212a) or Thrombin (Enzyme Research, cataloguenumber HT 1002a) at a final concentration of 1 unit/mg are added andincubated for 24 hours at 37° C. Next the Corn Trypsin Inhibitor (EnzymeResearch, CTI) at a final concentration of 200 nM and thefluorogenically-labeled substrate (1-1575, Bachem, final concentration25 μM) are added. The fluorescence is monitored continuously at 360/465nm using a SpectraFluorplus Reader (Tecan). Data are analyzed using theGraphPadPrism software as shown in FIG. 5 and FIG. 7 for the FXIIamediated conversion of FXI and in FIG. 6 and FIG. 8 for the Thrombininduced conversion of FXI into its activated form FXIa. Data are givenas mean±SEM, n=4.

Example 12: Evaluation of the Anti-Thrombotic Activity of the Anti-FXIaAntibody 076D-M007-H04 in an Experimental Thrombosis In Vivo Model inPrimates

Experimental Procedures

Experiments were conducted on non-anticoagulated awake juvenile baboonsweighing 9-11 kg. These animals had chronic exteriorized arterio-venous(AV) shunts placed between the femoral artery and vein, as describedelsewhere (Hanson et al. (1993) Journal of Clinical Investigation92:2003-2012). Baseline shunt blood flow exceeded 250 ml/min in allstudy animals. Anxiety was managed with low dose ketamine (<2 mg/kg/hr).Whole blood cell counts were measured daily, before and after theexperiments. Calculated blood loss did not exceed 4% of total bloodvolume on any experimental day a

Thrombus formation was initiated within the baboon AV shunt byinterposing a thrombogenic segment of prosthetic vascular graft (ePTFE,WL Gore & Co., Flagstaff, Ariz.), as previously described (Hanson et al.[1993] J. Clin. Invest. 92:2003-2012). To consistently triggerplatelet-dependent thrombus formation, the clinical graft segments werecoated with immobilized collagen. Twenty mm long grafts having internaldiameters (i.d.) of either 2 or 4 mm were filled with equine type Icollagen (1 mg/ml; Nycomed Arzenmittel, Munich, Germany) for 15 min, andthen dried overnight under sterile airflow. This method produced auniform collagen coating within the graft lumen as determined byscanning electron microscopy. In addition, in some experiments, a 20 mmlong chamber of 9 mm i.d. followed the 20 mm long graft with 4 mm i.d.to model average venous and arterial shear rates, respectively. Thethrombogenic collagen-coated grafts were then incorporated betweensegments of silicon rubber tubing, and deployed into the AV shunts. Thegrafts were exposed to blood for up to 60 min. During each experiment,the blood flow rate through the graft was restricted to 100 ml/min byclamping the proximal silicone rubber shunt segment, thereby producing amean wall shear rate (MWSR) in the 4 mm grafts of 265/sec, while in the2 mm grafts the initial MWSR was 2120/sec. Flow rates were continuouslymonitored using an ultrasonic flow meter (Transonics Systems, Ithaca,N.Y.). The 4 mm grafts did not occlude and pulsatile flow rates remainedat 100 ml/min until the thrombogenic graft segments were removed at 60min. Baseline blood flow was restored through the permanent shunt aftereach experiment. In the 2 mm diameter grafts blood flow ratesprogressively declined due to thrombus formation. The grafts wereremoved from the AV shunts when the flow rate fell from 100 ml/min tobelow 20 ml/min, signaling imminent occlusion. The time from initiationof blood flow to graft removal (<20 ml/min blood flow) was taken as theocclusion time.

For imaging of the platelet deposition, autologous baboon platelets werelabeled with 1 mCi of 111In-oxine as previously described (Hanson et al.[1993] J. Clin. Invest. 92:2003-2012). Labeled platelets were infusedand allowed to circulate for at least 1 h before studies were performed.Accumulation of labeled platelets onto thrombogenic grafts and siliconchambers were measured in 5-min intervals using a gamma scintillationcamera. Homologous 125I-labeled baboon fibrinogen (4 μCi, >90%clottable) was infused 10 min before each study, and incorporation ofthe labeled fibrin within the thrombus was assessed using a gammacounter >30 days later to allow the 111 In to decay. The radioactivitydeposited (cpm) was divided by the clottable fibrin(ogen) radioactivityof samples taken at the time of the original study (cpm/mg).

Occlusion studies were performed using 20 mm long, 2 mm i.d.collagen-coated devices which produced high initial wall shear rates(2120/sec at 100 ml/min clamped blood flow). Accumulation of labeledplatelets onto the 2 mm thrombogenic grafts were measured in 3-minintervals using a gamma scintillation camera. Flow was maintained at 100ml/min by proximal clamping for as long as possible, and then allowed todecrease as the propagating thrombus began to occlude the device. Afinal blood flow rate of 20 ml/min was used as a cutoff for occlusion,since a fully occlusive thrombi and lack of blood flow through thedevice could lead to occlusion of the shunt and a significant loss ofblood for the animals.

Blood sample analysis. Blood cell counts were determined using amicro-60 automated cell counter (Horiba-ABX Diagnostics). Blood sampleswere collected into a final concentration of 0.32% sodium citrate. Allsamples were centrifuged for 5 min at 12,900 g, and the plasmas werecollected and stored at minus 80° C. Cross-reacting ELISA assays wereused to determine thrombin-antithrombin complexes (TAT, Enzygnost-TAT,Dade-Behring; LOD: 2 ng/mL). All ELISA test kits utilized for thesestudies have previously shown sensitivity to baboon markers.

In interruption studies (4 mm i.d. collagen-coated graft only),076D-M007-H04 was administered as a bolus 30 minutes into the study (0.5mg/kg, i.v. bolus over 10 seconds) to determine whether this antibodycan interrupt acute thrombus propagation. In occlusion studies (2 mmi.d. collagen-coated graft only), 076D-M007-H04 was administered as abolus 3 hours before the experiment (0.5 mg/kg or 2 mg/kg 24 hoursfollowing a 0.5 mg/kg dose, i.v.). In prevention studies (4 mm i.d.collagen-coated graft followed by 9 mm i.d. silicon chamber),076-M007-H04 was administered as a bolus 1 hour before the experiment(0.5 mg/kg or 2 mg/kg 24 hours following a 0.5 mg/kg dose, i.v.).

Hemostatic assessment. The effects of FXIa inhibition on primaryhemostasis in baboons were assessed using the standard template skinbleeding time test (Surgicutt®, International Technidyne Corp).Experimentally, this and similar tests (e.g., Simplate bleeding times)have been shown to be sensitive to the effects of therapeuticanticoagulants, anti-platelet agents, and coagulation abnormalities inhumans and non-human primates (Gruber et al. [2007] Blood 109:3733-3740;Smith et al. [1985] Am. J. Clin. Pathol. 83:211-215; Payne et al. [2002]J. Vasc. Surg. 35:1204-1209). All bleeding time measurements wereperformed by the same expert technician. For indirect assessment ofhemostasis, aPTT (activated partial thromboplastin time; SynthASil,HemoslL; Instrumentation Laboratory Company, Bedford, Mass.) and ACT(activated clotting time, LupoTek KCT; r2 Diagnostics, South Bend, Ind.)measurements were also performed at various time-points before, during,and after the experiments.

In vitro aPTT. Various concentrations of 076D-M007-H04 were incubated inplasma for 10 minutes prior to the initiation of the aPTT assay. Asshown in FIG. 20, aPTT clotting times were determined in plasma samplescollected from the baboons at the “pre” time-point, i.e., before anytreatment was administered. Results show that 076D-M007-H04 wasanticoagulant in plasma from all 6 experimental baboons used in thethrombosis studies. In vivo clotting Studies. Three baboons were used inthese studies: two baboons were dosed with 076D-M007-H04 (2.5 mg/kg H04,i.v. bolus) after being given 32 m/kg chewable aspirin and 1 baboon wasdosed with 0.5 mg/kg 076D-M007-H04 (i.v. bolus) followed by a 2 mg/kgdose 24 hours later (i.v. bolus). ACT (FIG. 21 and FIG. 22) and aPTT(FIG. 23 and FIG. 24) were measured at various time-points followingadministration.

Platelet Deposition During Shunt Experiments.

Thrombosis occlusion experiments. The thrombogenic device that was usedto evaluate whether 076D-M007-H04 treatment can prevent occlusion of asmall blood vessel or prolong the time to occlusion consisted of a 2 mmi.d., 20 mm long collagen-coated graft. As shown in FIG. 25, plateletdeposition is shown for 60 minutes or until the time of graft occlusionwhen applicable. 12/14 control devices occluded within 60 minutes, while2/5 076D-M007-H04 (0.5 mg/kg) and 2/5 076D-M007-H04 (0.5 mg/kg+2 mg/kg)devices occluded. Data are means±SEM.

Thrombosis prevention experiments. The thrombogenic device that was usedto evaluate the effect of 076D-M007-H04 on thrombus initiation andpropagation consisted of a 4 mm i.d., 20 mm long collagen-coated ePTFEgraft that was followed by a 9 mm i.d., 20 mm long silicon rubberchamber. The slope of platelet deposition as shown in FIG. 26 is anindication of antiplatelet activity. Both doses of 076D-M007-H04 (0.5mg/kg and 0.5 mg/kg followed by 2 mg/kg 24 hours later) showed efficacyas evidenced by reduction in the rates of platelet deposition at varioustimes from the initiation of thrombus formation. The data have beennormalized to account for platelet count variations between experiments.Data are means±SEM.

As shown in FIG. 27 both doses of 076D-M007-H04 (0.5 mg/kg and 0.5 mg/kgfollowed by 2 mg/kg 24 hours later) showed efficacy as evidenced by theprofound reduction in the rates of platelet deposition in the siliconchamber at various times from the initiation of thrombus formation. Dataare means+SEM.

Thrombin anti-thrombin complexes. Since inhibition of FXI could reducethrombus formation in vivo both by limiting thrombin-mediated plateletactivation and fibrin formation and/or by increasing thrombolysis,levels of thrombin anti-thrombin (TAT) were measured using acommercially available ELISA kit. As shown in FIG. 28, pretreatment ofbaboons with 076D-M007-H04 (0.5 mg/kg and 0.5 mg/kg followed by 2 mg/kg24 hours later) prevented the increase in TAT levels, implying aprofound reduction in thrombin generation in the absence of FXIaactivity.

Bleeding Times. Primary hemostasis was evaluated using the adultSurgicutt device(http://www.itcmed/com/products/surgicutt-bleeding-time-device) that hasbeen approved by the FDA for use in children and adults. Bleeding time(BT) was manually recorded. The wound was observed for re-bleeding for30 minutes, and the skin was evaluated for bruising, petechiae,hematomas, and suffusions the next day. One or more of these hemostasisassessments have been shown to be sensitive and predictive of theantihemostatic effects of virtually all marketed antithrombotic agents(antiplatelet drugs, anticoagulants, thrombolytics).

Baboons were administered 076D-M007-H04 (0.5 mg/kg and 2 mg/kg 24 hourslater) alone or after they were given chewable aspirin (ASA, 32 mg/kg).As shown in FIG. 29 there was no increase in bleeding time with any ofthe 076D-M007-H04 treatments compared to baseline. Administration of076D-M007-H04 to aspirin-treated animals did not seem to furtherincrease the bleeding time compared to aspirin treatment alone.

The invention claimed is:
 1. A method for treatment of a thrombotic orthromboembolic disease or disorder and/or treatment and/or reduction ofa thrombotic or thromboembolic complication in a subject comprisingadministering an effective amount of a human monoclonal antibody thatbinds to coagulation Factor XIa comprising as CDRH1 SEQ ID NO: 21, asCDRH2 SEQ ID NO: 22 and as CDRH3 SEQ ID NO: 23 and as CDRL1 SEQ ID NO:24, as CDRL2 SEQ ID NO: 25 and as CDRL3 SEQ ID NO: 26 or SEQ ID NO: 28.2. The method of claim 1, wherein the human monoclonal antibodycomprises a variable light chain domain comprising the amino acidsequence of SEQ ID NO: 27 or SEQ ID NO: 19 and a variable heavy chaindomain comprising the amino acid sequence of SEQ ID NO:
 20. 3. Themethod of claim 1, wherein the thrombotic or thromboembolic disease ordisorder is selected from the group consisting of thrombotic stroke,atrial fibrillation, stroke prevention in arterial fibrillation (SPAF),deep vein thrombosis, venous thromboembolism (VTE), pulmonary embolism(PE), acute coronary syndromes (ACS), ischemic stroke, acute limbischemia, chronic thromboembolic pulmonary hypertension, systemicembolism, or atherothrombosis.
 4. The method of claim 1, wherein thethrombotic or thromboembolic complication is selected from the groupconsisting of acute VTE, primary and extended secondary prevention ofVTE, prevention of major adverse thromboembolic events in patientundergoing dialysis (with or without AF), prevention of majorcardiovascular and cerebral events (MACCE) in patients with CADundergoing PCI and receiving single or dual antiplatelet therapy,post-acute coronary syndromes (ACS) patients, heparin inducedthrombocytopenia (HIT), prevention of thromboembolic events in heartfailure patients or following surgery and secondary stroke prevention.5. A method for treatment and/or reduction of thrombosis orthromboembolism in a subject with end-stage renal disease comprisingadministering an effective amount of a human monoclonal antibody bindingto coagulation Factor XIa comprising as CDRH1 SEQ ID NO: 21, as CDRH2SEQ ID NO: 22 and as CDRH3 SEQ ID NO: 23 and as CDRL1 SEQ ID NO: 24, asCDRL2 SEQ ID NO: 25 and as CDRL3 SEQ ID NO: 26 or SEQ ID NO:
 28. 6. Themethod of claim 5, wherein the subject is receiving dialysis treatments.7. The method of claim 5, wherein the subject is receiving hemodialysisor other types of dialysis.
 8. The method of claim 5, wherein thesubject is afflicted with atrial fibrillation.
 9. The method of claim 8,wherein the subject is afflicted with non-valvular atrial fibrillation.10. The method of claim 5, wherein the subject is receiving hemodialysistreatments.
 11. The method of claim 10, wherein the effective amountreduces venous thromboembolism (VTE) risk in the subject.
 12. The methodof claim 5, wherein the human monoclonal antibody is capable of bindingto the C500S epitope of coagulation Factor XIa.
 13. The method of claim12, wherein the C500S epitope comprises amino acids His406, Pro410,Thr411, Gln412, Arg413, His414, Asn450, Gln451, Ser452, Ile454, Lys455,Arg522, Lys523, Leu524, Arg525, Asp526, Lys527, Ile528, Gln529, Asn530,and Thr531 of human Factor XIa.
 14. The method of claim 5, wherein theeffective amount inhibits thrombosis in the subject without compromisinghemostasis in the subject.
 15. The method of claim 14, wherein theeffective amount does not increase the risk of unwanted bleeding eventsin the subject.
 16. The method of claim 4, wherein the patientundergoing dialysis has end-stage renal disease.